




Cite this: *Biomater. Sci.*, 2024, **12**, 4875

Advances in implants and bone graft types for lumbar spinal fusion surgery†

Giles Michael Cheers, *^a Lucas Philipp Weimer,^a Carl Neuerburg,^a Jörg Arnholdt,^a Fabian Gilbert,^a Christoph Thorwächter,^a Boris Michael Holzapfel,^a Susanne Mayer-Wagner^a and Markus Laubach *^{a,b}

The increasing prevalence of spinal disorders worldwide necessitates advanced treatments, particularly interbody fusion for severe cases that are unresponsive to non-surgical interventions. This procedure, especially 360° lumbar interbody fusion, employs an interbody cage, pedicle screw-and-rod instrumentation, and autologous bone graft (ABG) to enhance spinal stability and promote fusion. Despite significant advancements, a persistent 10% incidence of non-union continues to result in compromised patient outcomes and escalated healthcare costs. Innovations in lumbar stabilisation seek to mimic the properties of natural bone, with evolving implant materials like titanium (Ti) and polyetheretherketone (PEEK) and their composites offering new prospects. Additionally, biomimetic cages featuring precisely engineered porosities and interconnectivity have gained traction, as they enhance osteogenic differentiation, support osteogenesis, and alleviate stress-shielding. However, the limitations of ABG, such as harvesting morbidities and limited fusion capacity, have spurred the exploration of sophisticated solutions involving advanced bone graft substitutes. Currently, demineralised bone matrix and ceramics are in clinical use, forming the basis for future investigations into novel bone graft substitutes. Bioglass, a promising newcomer, is under investigation despite its observed rapid absorption and the potential for foreign body reactions in preclinical studies. Its clinical applicability remains under scrutiny, with ongoing research addressing challenges related to burst release and appropriate dosing. Conversely, the well-documented favourable osteogenic potential of growth factors remains encouraging, with current efforts focused on modulating their release dynamics to minimise complications. In this evidence-based narrative review, we provide a comprehensive overview of the evolving landscape of non-degradable spinal implants and bone graft substitutes, emphasising their applications in lumbar spinal fusion surgery. We highlight the necessity for continued research to improve clinical outcomes and enhance patient well-being.

Received 25th June 2024,
Accepted 14th August 2024

DOI: 10.1039/d4bm00848k

rsc.li/biomaterials-science

1. Introduction

Spinal fusion, a surgical procedure designed to stabilise the spine and alleviate nerve compression by fusing two or more vertebrae, is essential for managing a spectrum of degenerative spinal conditions. This intervention becomes necessary when non-surgical treatments for spinal pathologies, encompassing degenerative disc disease, spondylolisthesis, spinal fractures,

spinal stenosis, and spondylolysis, prove inadequate. Notably, these spinal disease entities contribute to more than half of the musculoskeletal diseases in the United States (US) (51.7% or 15.4 million incidents),¹ increasing by more than 60% in the last two decades.² The most significant growth rate is observed in the demographic aged 65 and over, which is attributed to factors including an ageing population, changing lifestyles – amongst others marked by a higher incidence of obesity – and improved patient awareness of fusion procedures.^{2,3} However, spine surgery revision rates of 10% to 20% are a significant challenge for patients, surgeons, and the healthcare system in general.^{4–7}

The challenges of lumbar spinal fusion surgery are rooted in the anatomical exposure of adjacent, highly vulnerable structures, and the difficulty of translating recent advancements in its essential components from research into clinical practice. These components include spinal instrumentation for posterior lumbar stabilisation, spinal cages for lumbar

^aDepartment of Orthopaedics and Trauma Surgery, Musculoskeletal University Center Munich (MUM), LMU University Hospital, LMU Munich, Marchioninistraße 15, 81377 Munich, Germany. E-mail: Giles.Cheers@med.uni-muenchen.de, Markus.Laubach@med.uni-muenchen.de

^bAustralian Research Council (ARC) Training Centre for Multiscale 3D Imaging, Modelling and Manufacturing (M3D Innovation), Queensland University of Technology, Brisbane, QLD 4000, Australia

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d4bm00848k>





Fig. 1 Anatomical exposure of adjacent, highly vulnerable structures in lumbar spinal fusion surgery and its main components of posterior stabilization (1), interbody cage (2) and bone graft (3). Particularly during anterior approaches to the lumbar spine, the bowel (a) and blood vessels (b) can be damaged. Potential complications during lumbar spinal fusion surgeries or during the post-operative follow-up include vertebral body osteomyelitis/fracture (c), psoas muscle abscess/injury (d), adjacent segment disease (e) and spinal/epidural abscess/injury (f). Adapted from supplement of ref. 8 with permission from Elsevier, copyright (2022) and partially created with BioRender.com.

interbody fusion, and bone grafts aimed at facilitating spinal fusion (Fig. 1). Thus, to have a thorough understanding of these inherent challenges necessitates a comprehensive exploration into the historical developments of lumbar spinal fusion,⁸ while also concentrating on its primary components: spinal instrumentation, intervertebral body fusion devices and bone grafts. Drawing on both historical and contemporary evidence, this narrative review seeks to provide a comprehensive overview and critical analysis of the most significant developments, which are crucial for guiding future research and enhancing the clinical success of lumbar spinal fusion.

2. Key historical events

The earliest descriptions of treatments for spinal deformity trace back to ancient Indian religious literature, specifically

the *Srimad Bhagwat Mahapuranam*. This text recounts a Hindu mythological epic in which Lord Krishna corrects a “hunch-back” by anchoring the patient’s foot with his own and applying axial traction by pulling the patient’s chin with two fingers.⁹ The principle of axial traction for spinal deformity correction endured for millennia. Advancements of several existing corrective procedures are further rooted in early spinal treatment descriptions applied by Hippocrates (460 BC to 377 BC), Galen (131 AD to 201 AD) and Ibn Sena (980 AD to 1037 AD).^{9–11} Nonetheless, the breadth of spinal surgical treatment options witnessed significant evolution only following the profound discoveries of general anaesthesia (1846), antisepsis (1867) and the advent of X-ray (1895).^{12–14} The rise of (spinal) tuberculosis, including Pott’s disease in the 18th and 19th centuries,^{15,16} resulted in the need to develop alternative stabilising methods due to frequently observed severe destruction of vertebral bodies and intervertebral discs.¹⁷ The goal of



instrumented spine surgery has thus notably shifted in the last century from a method of correcting deformities, to one of restoring stability and maintaining natural balance.¹⁷ Traditionally, the absolute indications for lumbar interbody surgery were lumbar spondylolisthesis, severe scoliosis, spinal tuberculosis, and fractures, some of which have gradually shifted more towards relative indications such as back pain, degenerative disc disease, and spinal stenosis.¹⁸

2.1 The genesis of interbody fusion techniques

In 1933, Capener pioneered the anterior fusion of the L5 (fifth lumbar vertebra) and S1 (first sacral vertebra) using a tibial graft peg for treating spondylolisthesis. Despite its biomechanical advantages, this approach faced resistance among clinicians due to its invasiveness.¹⁹ A decade later, Cloward performed the first posterior lumbar interbody fusion (PLIF) without posterior instrumentation; a procedure involving the removal of the intervertebral disc, including the cartilaginous endplates, through a partial bilateral laminectomy and essentially a complete facetectomy. Subsequently, Cloward performed autologous implantation, placing three or more large full-thickness bone grafts obtained from the iliac crest.²⁰ Historically, bi- and tri-cortical structural bone grafts, such as autologous bone from the iliac crest or fibula, and allografts, were implanted in the intervertebral space to stabilise the spine and to achieve spinal fusion. However, these alternatives are associated with relevant donor site morbidity and insufficient spinal stability.^{21–25} Spinal fusion with bone graft alone is linked to a notable incidence of autograft or allograft collapse, eventually leading to pseudarthrosis.²⁶ To address these complications, additional posterior stabilisation with pedicular screws interconnected with rods gained popularity in the 1980s to achieve spinal fusion (posterolateral instrumentation/fusion).

Current surgical techniques of spinal fusion rely heavily on autologous bone graft (ABG) or bone graft substitutes to achieve adequate bone healing and solid fusion.²⁷ ABG remains crucial for stabilisation due to its inherent properties of osteogenic potential, osteoinductivity, and osteoconductivity.^{28–30} Modern practices involve morselising ABG to enhance its osteogenic potential and facilitate its integration within the intervertebral space and hollow regions of cages. Furthermore, ABG is placed around the screw-rod construct to facilitate the posterior fusion of adjacent bone surfaces.³¹ The iliac crest is frequently used as a source for harvesting cancellous ABG; however, its application is constrained by several factors. These include the restricted size and volume of obtainable bone grafts, donor site morbidity that can lead to persistent pain in up to 30% of patients post-harvesting,^{32–34} and the presence of a limited quantity of viable and biologically active cells within the graft.³⁵ Additionally, the number of stem cells present in the graft notably decreases after the age of 55.³⁶ The anatomical site from which ABG is harvested – be it the iliac crest, lamina, or during decortication – affects the graft's composition and subsequently influences its regenerative capacities.^{37–39}

Nonetheless, rates of non-union after lumbar spine fusions range from 5% to 35%⁴⁰ and are associated with the unsatisfactory resolution of clinical symptoms.⁴¹ Spine surgery revision rates of 10% to 20% pose a significant challenge for patients, surgeons, and the health care system in general.^{4–7} Consequently, a rigorous evaluation of the current treatment approach is warranted to support future preclinical and clinical research aimed at developing more sophisticated techniques leading towards more effective spinal fusion.

2.2 The introduction of interbody spacers

The application of interbody spacers, or 'cages', was first described by Bagby⁴² in the context of treating equine wobblers disease, involving arthrodesis through the distraction-compression method using a stainless steel cylindrical, fenestrated implant. Adapted for human use, the Bagby and Kuslich method of interbody stabilisation for chronic discogenic lower back pain incorporated the "Bagby Basket" with ABG rather than relying on ABG alone. This presented good fusion rates for lumbar interbody fusion.⁴³ Bagby and Kuslich (BAK) cages (SpineTech, Minneapolis, MN) achieved a 20% fusion success at six months with the addition of autograft, and reached a 100% fusion rate when it was combined with recombinant human bone morphogenetic protein-2 (rhBMP-2).⁴⁴ Thus, using interbody cages provided further stability and fusion by restoring disk height and neuroforaminal volume.^{45,46}

Throughout the 1990s, spinal interbody fusion with conventional metallic cages, primarily titanium-aluminium-vanadium (Ti6Al4V or Ti), gained widespread commercialisation. While titanium offers durability, strength, osteoconductivity, and resistance to corrosion, its high elastic modulus introduces complications in the form of stress-shielding, endplate trauma, adjacent segment disease, and cage subsidence.^{47–49} In the early 2000s, the use of polyetheretherketone (PEEK) cages gained in prominence as it has a favourable elastic modulus akin to bone, which typically aids in lowering subsidence rates.⁵⁰ However, PEEK's bioinert nature diminishes its osteointegrative capacity, and challenges such as the need for greater endplate preparation and issues with over distraction compromise its effectiveness.⁵¹

The historical progression from traditional metallic cages to the adoption of PEEK marked a significant shift in addressing biomechanical challenges. While each material brings its specific advantages, the pursuit for an ideal balance between strength, osteoconduction, and biocompatibility spurred further innovations. The 2010s witnessed the introduction of hybrid materials and surface modifications, giving rise to the development of Ti-coated PEEK (Ti-PEEK) composite materials. This innovation amalgamated PEEK's mechanical advantages with the desired biocompatibility characteristics of Ti. The increasing popularity of additive manufacturing from the late 2010s allowed the creation of biomimetic structures resembling the porosity and biomechanical properties of cortical bone. This technological leap has paved the way for interlayer-mediated cages with osteoconductive coatings and topo-



graphical modifications, aiming to optimise the cages' osteoinductive, osteoconductive, and osteogenic properties. While larger clinical trials are needed to validate the efficacy of these devices, *in vitro*, *in vivo*, and initial clinical trials have demonstrated their viability.^{52–58} However, primary concerns such as delamination and inflammatory responses due to wear remain significant challenges.^{59–61}

Despite advancements in selective laser sintering (SLS) manufacturing of titanium implants, which improve the biomimetic properties and biomechanical performance of Ti spinal cages, PEEK remains the most cited material for spinal surgery.⁶² Fused deposition modelling (FDM) of PEEK is more cost-effective compared to SLS, which may contribute to its continued prevalence in spinal surgery.




Fig. 2 Chronology highlighting major milestones in clinical lumbar spine surgery, tracing the evolution of bone graft materials, interbody cages, and pedicle screws and rods, with a specific focus on advancements in interbody spinal fusion.



2.3 Synergies in posterior lumbar stabilisation

In the late 20th century, the advent of the standardised use of posterior spinal instruments led to a transition to circumferential (360°) fusion in clinical practice, which further improved clinical outcomes and increased the robustness of results.^{63,64} Therefore, it can be deduced that the success of lumbar spinal fusion hinges on the synergistic interplay of various components – namely, spinal instrumentation, intervertebral body devices (cages), and ABG or bone graft substitutes (Fig. 2). To achieve an ‘ideal’ lumbar stabilisation model, characterised by a biomimetic approach mirroring the structure and properties of natural bone extracellular matrix (ECM), a comprehensive understanding of these elements is imperative. This analysis delves into the individual roles of these components, offering a concise overview coupled with critical discussions on advancing research.

3. Anterior/posterior lumbar fusion: 360° spinal stabilisation

3.1 Pedicle screws

Pedicle screw fixation was first introduced in the context of thoracolumbar segmental fixation in 1963 by Roy-Camille.⁶⁵ Initially designed for fractures, pedicle screws have since evolved to address various spinal conditions, including tumours, spondylolisthesis, fractures, and malunions. The initial pedicle screw design featured a fixed-headed, monoaxial approach, placed sagittally through the pedicles and articular processes, coupled with plates.⁶⁶ The progression of pedicle screw design includes the integration of patient-specific contoured rods, marking a significant advancement in spinal deformity correction.⁶⁷ Positioned in the most structurally robust region of the vertebrae, this instrumentation plays a pivotal role in achieving immediate immobilisation, enhancing the bone–screw interface, and thereby improving the biomechanical performance of the screws, allowing for optimal leverage to exert higher corrective forces on the deformed spine.

However, the conventional monoaxial screw design has limitations in manoeuvrability, presenting challenges in aligning the screw with the rod head saddle. To address this, Harms introduced the polyaxial pedicle screw in 1989, aiming to facilitate a more straightforward coupling of fixation points with rods. While polyaxial pedicle screw fixation has demonstrated an association with less adjacent segment degeneration, likely attributed to lower von Mises stress in screws and reduced intradiscal pressure in the adjacent segment,⁶⁸ its enhanced manoeuvrability comes at the expense some construct strength, making polyaxial screws more susceptible to fatigue failure or breakage.

Despite the widespread adoption of polyaxial screws, the use of monoaxial screws or a combination of both types persists, aiming to optimise biomechanical performance in fixation constructs. For instance, in the treatment of thoracolumbar

fractured vertebrae, monoaxial pedicle screws may be preferable due to their enhanced leveraging effect, providing increased stability during flexion and extension of the spine.^{68,69} This choice also contributes to improved uplift and restoration of the collapsed superior endplate. Similarly, hybrid constructs, incorporating both mono- and poly-axial screws or uniplanar screws, allow freedom of movement in assembly without sacrificing construct stiffness in the sagittal plane.^{70,71}

3.1.1 Anchor and tip types. The integrity of the bone–screw interface plays a pivotal role in ensuring the stability and pull-out strength of pedicle screws. Fig. 3 illustrates the diverse anchor and thread types that have been developed to enhance this metric. Pedicle screws are subjected to significant cyclic axial and lateral forces. The strength of these screws is directly proportional to the cube of the minor core diameter, with larger diameters offering greater resistance to screw bending or breakage. The pull-out resistance of the screw is influenced by factors such as the major (outside) diameter, thread depth, pitch, and shape. Notably, the thread pitch determines the volume of bone between the threads, which is directly proportional to pull-out resistance. The selection of inadequate anchor or thread types can lead to complications such as screw loosening or breakage. Many pedicle screws are cannulated to facilitate accurate implantation with a guide wire and features a standard threaded anchor. Given that lower bone density correlates with decreased strength in the bone–screw interface, leading to loosening and pull-out – particularly observed in elderly patients suffering from osteoporosis – various other anchor and screw types have been developed.^{72–74} These aim to increase the surface area attached to the cortical bone, thus enhancing interface stability.

In the context of screw types, tapping and non-tapping screws play distinct roles. Tapping screws, through their design, create threads in the bone, providing a pre-formed path for the screw to follow during insertion. This process reduces the risk of generating excessive heat, preserving bone integrity. Non-tapping screws, conversely, lack pre-formed threads and engage directly with the bone as they are inserted. While non-tapping screws offer advantages in terms of reduced thermal damage, tapping screws may be preferred in certain scenarios for their simplicity and efficiency. Multithreaded screws, for instance, have been employed to generate locking forces. In this design, the screw interfaces between proximal-cortical, middle-cancellous, and distal-cancellous screw–bone segments are compressed against each other. This approach is typically complemented by a conical or dual-core screw type, enhancing load-bearing capacity, potentially minimising screw breakages,^{75,76} and ensuring optimal contact between the screw and bone surfaces. The combination of these design features contributes to the overall stability and longevity of the pedicle screw fixation in challenging bone conditions.

3.1.2 Biomaterials. Since screws redirect force through the vertebral bodies they are commonly made of strong as well as bioinert material such as Ti6Al4V. Complications associated






Fig. 3 The various features found in commercial pedicle screws, including different anchor, thread, and tip types, are designed to influence the screw's biomechanical performance and integration with bone. Adapted from ref. 72 with permission from Springer Nature, copyright (2022). Adapted from ref. 73 with permission from MDPI AG, copyright (2022).

with pedicle screw placement which can affect bone healing include loosening, pull-out, and screw breakage. Pull-out resistance of screws is affected by the bone mineral density, the screw insertion technique and factors directly influencing the screw such as metal properties, and geometry. The holding power is further improved when self-tapping screws are used, however only when multiple time insertion is avoided. To improve screw performance coating and doping with various materials such as hydroxyapatite (HA), calcium phosphate (CaP), polymethylmethacrylate bone cement (PMMA-BC), ECM, tantalum (Ta), and Ti plasma spray have been investigated.^{77–81} In preclinical animal models coating of Ti6Al4V screws with HA was shown to improve resistance against pull-out force⁷⁷ and bone-to-implant contact.⁷⁸ When comparing HA, CaP, and PMMA-BC against control only PMMA-BC showed increased pull-out strength while it is noteworthy that rigid and solidified cement structure limits any post insertion modification.⁷⁹ Further, thin Ta coating of

Ti6Al4V pedicle screws exerted an inhibitory effect on osteoclasts and promoted trabecular bone growth *in vivo*.⁸⁰ Coating of pedicle screws with the combination of ECM and HA improved pull-out strength compared to uncoated screws or coating with HA or ECM alone.⁸¹ However, the translation into clinical use is scarce and future clinical studies are necessary to define the role of specific screw coatings to improve pull-out force and spinal stability.

3.2 Spinal rods

Spinal rods have been routinely used for treating spinal deformities since the introduction of the “Harrington rod” for the treatment of scoliosis in 1962.⁸² In recent years, they have emerged as a standard and indispensable component of lumbar interbody fusions.^{83,84} These rods play an essential role in load distribution during instrumented (posterior) spinal arthrodesis. Strategically positioned along each spinal process side and affixed to the pedicle screws, these implants



are manually contoured to a specific fit during surgery. They feature a diverse range of diameters that provide varying levels of stiffness, ensuring an optimal fit to the patient's individual spinal pathology. Due to its use in conjunction with other spinal implants such as screws and side-to-side connectors, spinal rods ideally establish a controlled environment that evenly distributes loads across the vertebral segment(s). This promotes a conducive setting for bone fusion. Therefore, the selection of biomaterials for spinal rods should prioritise stability and stiffness required by the individual patient, as these factors are crucial for immobilising interbody vertebrae, fostering bone fusion, and safeguarding bone graft integrity.

3.2.1 Biomechanical stability. Metallic-based rod systems, mainly composed of stainless steel, have traditionally been crucial in spinal instrumentation due to their inherent stability and stiffness.⁸⁵ This rigidity is essential for spinal immobilisation, facilitating interbody fusion and ABG integration stabilising the posterior screw-rod constructs. However, the use of such materials, while effective in achieving successful arthrodesis, presents challenges. The use of supraphysiological rigid materials may cause stress shielding and improper load sharing, which can lead to issues such as adjacent segment disease.⁸⁶ This is due to the excessive stress imposed on neighbouring vertebrae. In cases where there is excessive load sharing, the mechanical load is distributed between the implant and surrounding vertebral bodies, resulting in a reduction in load through the bypassed vertebral body. As a living tissue, bone requires mechanical loading to maintain its density and strength. Therefore, the reduced mechanical strain on the bone of the bypassed vertebral body, while promoting fusion and immediate stability, can lead to bone mineral loss over time.⁸⁶ This phenomenon is known as disuse osteoporosis or bone demineralisation.

To address these concerns, contemporary dynamic and flexible alternatives such as porous Ti and titanium alloys (pTi and Ti6Al4V), or polymers like PEEK, have been favoured for their superior biomechanical properties, closer resemblance to Young's modulus of bone, and enhanced biocompatibility.^{87,88} However, the semi-rigidity of polymer alternatives has led to its own suite of complications, including screw loosening, infection, back and leg pain, and endplate vertebral fracture. PEEK rods are a popular choice for semirigid rods due to their comparable stability to Ti rods⁸⁹ and are associated with lower incidence of adjacent segment disease.⁹⁰ Theoretical advantages include improved biological compliance, elasticity, and radiolucency. However, some studies have reported increased rates of pseudarthrosis and early reoperations due to an unstable screw interface.⁹¹ Future research could investigate materials with matching Young's Moduli, high bending strength, and high tensile strength. In particular, beta-type Ti-molybdenum and oxygen-modified beta-type Ti-chromium alloys possess desirable mechanical properties to mitigate stress-shielding and have good cytocompatibility.^{83,92,93} Future *in vivo* studies are required to test the efficacy of these materials for spinal rod applications.

Furthermore, the feasibility of biodegradability for rods in lumbar spinal fusions remains uncertain.^{83,94} Tsuang *et al.*⁹⁴ demonstrated *in vitro* that biodegradable rods can withstand comparable dynamic compression cycles under axial load to standard Ti rods. However, they observed a 20% and 80% decrease in Young's modulus after six and 12 months, respectively, which could potentially impair spinal stability *in vivo*. Future preclinical large animal studies may shed light on the applicability of biodegradable rods for posterior lumbar fusion before clinical trials may be conceived.

3.2.2 Notch effect. Despite advancements in material choices and surgical techniques, it is important to note that the process of rod contouring, typically performed with a French Bender, introduces notch points that compromise the rod's durability by imparting marks and weaknesses⁹⁵ (Fig. 4). This is otherwise known as notch sensitivity.⁹⁶ Therefore, in addition to the screw-rod junction these notch-points are susceptible to rod fatigue, fractures, and significant deformation.⁹² Recent advancements in preoperative planning software have led to the development of patient-specific spinal rods, which address the limitations of traditional contouring methods.⁹⁷ Unlike conventionally contoured rods, these rods do not require on-site shaping during surgery. It has the potential to reduce surgical time, minimise the occurrence of rod microfractures, increase fatigue life, and lead to fewer mechanical complications. The integration of patient-specific spinal rods is a promising advancement in arthrodesis procedures, potentially reducing proximal junctional failure.⁹⁸ This showcases a step towards enhancing the overall durability and performance of spinal instrumentation.

3.2.3 Corrosion resistance and biocompatibility. Additional research has explored materials such as nickel (Ni), nitinol (NiTi), and cobalt-chromium alloys (CoCr). These metals are biocompatible due to the stable oxide layer that protects against corrosion.¹⁰⁰ Cobalt-chromium rods, which are more rigid than stainless steel rods, have demonstrated potential in treating adolescent idiopathic scoliosis when compared to Ti rods.^{101,102} Furthermore, while theoretical drawbacks such as increased artefacts on magnetic resonance imaging (MRI) compared to Ti have been noted, clinical studies have found no impairment of the spinal canal or neural elements from such CoCr artefacts.¹⁰³ Nitinol does not evoke an inflammatory response from the lymph nodes or other organs¹⁰⁴ and exerts shape recovery forces, making it a valuable material for scoliosis correction. Additionally, NiTi rods have been used for spinal instrumentation due to their wear resistance comparable to CoCr and 100 times higher compared with Ti.¹⁰⁵ However, its lower Young's modulus compared to Ti or stainless steel rods, and higher costs make this material less attractive for spine surgery, particularly lumbar spinal fusion.¹⁰⁶ Incorporating materials like CoCr and NiTi in spinal instrumentation offers promising alternatives to stainless steel or titanium, providing both biocompatibility and mechanical advantages. However, careful consideration of clinical implications, keeping in mind the cost-to-benefit ratio, is essential for their potential application in lumbar spinal fusion.¹⁰⁷






Fig. 4 Surface defects and curvature deformation of the spinal rod can compromise its durability. Panels A and B show the surface impressions caused by pedicle screw fastening, while the black arrow in panel C indicates the notch imparted by the French bender, an instrument commonly used to contour the spinal rod to the patient's spine. These defects can significantly affect the rod's biomechanical performance and longevity. Reproduced from ref. 99 with permission from Elsevier, copyright (2019). Reproduced from ref. 86 with permission from Elsevier, copyright (2013).

3.3 Spinal cages for lumbar interbody fusion

The selection of an interbody cage in lumbar interbody fusion is intrinsically linked to the chosen surgical approach, aligning to the geometry and material properties of the bony endplate. Five primary approaches have been developed to address the complexities of spinal disorders – Posterior Lumbar Interbody Fusion (PLIF), Transforaminal Lumbar Interbody Fusion (TLIF), Anterior Lumbar Interbody Fusion (ALIF), extreme Lateral Lumbar Interbody Fusion (XLIF), and Oblique Lumbar Interbody Fusion (OLIF) as illustrated in Fig. 5. Notably, there is no conclusive evidence indicating the superiority of one approach over another,¹⁰⁸ however, inherent advantages and disadvantages may lean towards specific indications for particular lumbar spine pathologies.^{84,109}

PLIF employs dual ovoid-shaped spacers packed with bone graft, offering comprehensive decompression and fusion capabilities through a posterior approach. With relatively low complications, it avoids vascular and neurological risks associated with anterior approaches, providing a single-incision option for bilateral decompression and interbody fusion.¹⁰⁸ TLIF utilises a single kidney-shaped implant supplemented with bone graft for interbody fusion, avoiding anterior exposure and associated complications such as vascular and abdominal wall issues. Due to the unilateral hemilaminectomy (compared to bilateral hemilaminectomy with PLIF), TLIF is in theory superior to PLIF in terms of biomechanical stability, but a certain learning curve is necessary as significant muscle retraction and dissection can occur, which in turn can impact post-

operative pain and rehabilitation.¹⁰⁸ ALIF implants a single, wedge-shaped cage through an anterior approach, preserving posterior spinal elements and offering a viable option for revision surgery. However, it presents challenges related to intraabdominal and vascular complications, and lower fusion rates compared to PLIF and TLIF due to limitations in using local bone graft.¹⁰⁸ XLIF uses a single ovoid implant through a transpsoas approach, providing good anterior column support with advantages such as avoiding major vascular manipulation. However, it has exposure limitations and risks damaging neural structures within the psoas muscle, leading to potential sensory and motor deficits.¹⁰⁸ OLIF, like XLIF, places a single ovoid spacer without traversing the psoas muscle, making it suitable for various degenerative conditions and deformity corrections. While allowing aggressive deformity correction and achieving high fusion rates, OLIF introduces potential risks such as sympathetic dysfunction and vascular injury.¹¹⁰

The gold standard of a solid 360° interbody fusion (interbody spacer plus posterior pedicle screw-and-rod instrumentation)¹¹¹ includes a radical debridement of the (infected) disc to facilitate intervertebral fusion using either interbody cages and/or ABG with or without additional decompression of the spinal canal.^{112–115} Due to its high corrosion resistance and biocompatibility Ti and its alloys are successfully employed as artificial implants, such as interbody cages, in orthopaedic surgery.¹¹⁶ Nevertheless, the ongoing risk of infection, challenges in radiographically assessing fusion, and adjacent segment diseases frequently linked to its greater stiffness com-






Fig. 5 Surgical approaches for lumbar interbody fusion and their respective interbody cage designs. A transverse section through the abdomen highlights the anatomical structures encountered in each surgical approach, illustrating potential challenges and risks for different types of surgeries. Figure created with BioRender.com.

pared to human bone have led to the exploration of cages made from alternative materials.^{117,118} The underlying causes of non-union and cage subsidence are multifactorial, including surgical techniques and bone quality,^{119–121} but the bone-hardware interface's ability to act as a biomechanical unit against axial loading stress is critical in preventing subsidence.¹²² Laboratory studies by¹²³ demonstrate that stress shielding and subsidence can be mitigated by developing implants that mimic the properties of bone. Therefore, intervertebral body implants manufactured from PEEK are regularly used due to the polymer's radiolucency, proven biocompatibility, and an elastic modulus of 4.0 GPa, which closely approximates that of cortical bone (4.89 GPa) compared to Ti (105 GPa).^{54,124,125} Furthermore, technological advances allowed for the development of Ti-PEEK composite materials combining the mechanical advantages of PEEK with the desired biocompatible characteristics of Ti.

Moreover, current research focuses on a variety of technologies for the production of antibiotic and non-antibiotic antimicrobial pro-osteogenic implants, ranging from inherently antimicrobial implants based on the effects of chemistry or topography to the application of antimicrobial metal ions and oxides, polymers or peptides.¹²⁶ In line, preclinical and clinical outcomes in the last decennia stress the importance of

implant designs in orthopaedics aiming to improve implant characteristics, such as Young's modulus, compression strength, biocompatibility, and surface topography.^{127–129} Such features are highlighted by the 'ideal' interbody cage characteristics in Fig. 6.

3.3.1 Titanium cages. Titanium cages have high mechanical stability and can be manufactured in a variety of designs and surface structures. The merits of Ti interbody implants include their high mechanical strength under physiological loads, low density, high corrosion resistance, and good biocompatibility.^{60,130,131} Titanium and its alloys are widely utilised in orthopaedic surgery due to their resistance to corrosion and biocompatibility.¹¹⁶ While segmental spinal fusion effectively alleviates pain by addressing spinal instability, conventional metallic cages pose complications, including increased adjacent level (disc) disease due to its high stiffness, causing stress shielding, implant migration or subsidence, device-related osteopenia and imaging artefacts.^{47–49} Particularly, postoperative follow-up for bone healing determination is often impaired by radiopaque metallic cages, impeding the visualisation of bony fusion at the graft site.^{8,132–134} Superior biological response including the promotion of bone formation *in vitro* has been observed for intervertebral body implants manufactured out of Ti alloy compared to PEEK.^{59,130}






Fig. 6 The essential elements of an 'ideal' lumbar interbody cage design include stability, porosity and pore size, and surface topography. The choice of materials (e.g., titanium, PEEK, composites) and geometry (e.g., Voronoi tessellation, TPMS, auxetic structures) helps to biomimetically replicate the structure and stiffness of native bone, enhancing stability and reducing stress shielding.^{127–129} Optimal porosity and pore size are crucial for osteoinductivity, vascularization, and cell proliferation.^{153–156} Changes to surface topography and coatings can help to improve osteoconductivity, cell adhesion, and reduce infection risk through antibiotic coatings.¹²⁶ Figure created with BioRender.com. Scaffold created with nTop, Release 4.21.1, nTop Inc., <https://ntop.com>.

Preclinical large animal studies comparing Ti and PEEK devices in lumbar fusion models show comparable patient range of motion and fusion rates. Although titanium cages exhibit higher subsidence rates than PEEK cages, clinical outcome variables remain insignificantly different.^{50,135} However, in the osteoporotic spine, bone stress concentration and absorption may lead to the instability or sinking of Ti (mesh) cages.¹³⁶

3.3.1.1 Surface modifications. Enhancing osteointegration in cages can be achieved through surface modifications, particularly by incorporating rough and porous Ti surfaces.^{137–139} Surface roughness, influenced by techniques like plasma spraying, electron beam (e-beam) melting, sandblasting/acid treatment, and 3D printing, positively induce cell adhesion and proliferation. Roughening a smooth surface has been shown to promote osteointegration by increasing osseous tissue apposition, favouring epithelial attachment to the implant, especially on Ti surfaces.^{140–142} Coating techniques involve adding a calcium-phosphate-based mineral film similar to bone mineral,^{143–146} and incorporating osteogenic growth factors to mineral coatings as delivery vehicles.¹⁴⁷ Mineral coatings with “bone-like”-films significantly enhance the osteoconductivity and osteoinductivity of orthopaedic implant materials.^{148,149} For instance, Ti implants subjected to sandblasting with alumina grit (0.25–0.50 mm) followed by etching in HCl/H₂SO₄ acid bath have shown increased bone anchorage in a large animal study.¹⁵⁰ Pelletier *et al.*¹³⁴ observed in their large animal lumbar fusion model that

treated Ti endplates had greater bone apposition compared to polished internal Ti surfaces or PEEK. Moreover, rough Ti alloy compared to smooth Ti alloy or PEEK was shown to stimulate cells in creating an osteogenic–angiogenic micro-environment *in vitro*. This includes the expression of integrins crucial for collagen recognition and enhanced osteoblast maturation.^{59,151} Microroughened Ti surfaces demonstrate increased osteoblast differentiation and protein production, associated with bone formation and decreased bone resorption.¹⁵² Further, the bioactivity of porous Ti cages can be enhanced through chemical and thermal treatments.¹⁵⁷ Modifications of Ti surfaces by addition of nanoparticles such as Ti oxide (TiO₂) and zirconia (ZrO₂) are also possible. By adjusting the nanostructure of the surface of Ti implants in terms of titanium dioxide (TiO(2)) nanotubes, Bjursten *et al.*¹⁵⁸ observed improved bone bonding strength, greater bone–implant contact area, new bone formation, and calcium and phosphorus levels on the nanotube surfaces compared with TiO(2) grit blasted surfaces. Thereby, these surface technologies potentially increase the rate of fusion by fostering osteointegration at interfaces of both endplate–implant and bone graft–implant. However, surface modification of blasting or acid etching of Ti implants and porous coatings may cause crack initiation potentially influencing its fatigue and bending strength.^{159,160}

In recent decades, orthopaedic implants, particularly Ti and Ti alloys, are successively shifting from the early premise of mechanical strength to biocompatibility, fast osteointegra-



tion to multifunctional properties including the function of antibacterial actions as well as modulation of inflammation. Instrumentation failure related to microbial infections of Ti implants are a heavy burden on patient health and healthcare costs.¹⁶¹ Titanium surfaces may be rendered antibacterial to decrease bacterial infections by surface modification and coatings (chemical or physical).¹⁶² Gentamicin-coated tibial nails have already been successfully used in patients with high infection risk¹⁶³ and *in vitro* cytocompatibility and antimicrobial activity has been shown for hybrid surfaces of porous Ti structure, silver particles in the Ti dioxide layer, and gentamicin-loading.¹⁶⁴

3.3.1.2 Porous titanium cages. Recent developments in fabrication techniques for selective laser melting, and e-beam laser melting allow for the wide use of Ti.¹⁶⁵ Porous implants, compared to solid metal implants, are more lightweight, offer larger contact surfaces, and may possess mechanical properties that more closely resemble human bone. Furthermore, advanced additive manufacturing techniques enable the printing of porous metallic scaffolds that more accurately mimic bone's complex 3D inhomogeneous structure, featuring intricate details from the macro- to the nano-scale.^{166,167} When selecting pore shape, size, and overall porosity, it is crucial to carefully consider mechanical properties and intended functionality, as these factors significantly influence the mechanical behaviour of porous metallic biomaterials.¹⁵⁴ Additionally, they affect biological performance, including cell adhesion and proliferation, nutrient transport, and the osteointegration of the implant.^{153,155} Porous Ti cages with a porosity of 60% to 70%, pore sizes ranging from 250 to 750 μm , and pore interconnectivity greater than 99% can be fabricated with high mechanical strength.¹⁵⁶

In silico analyses suggest that porous cages with a porosity between 65% and 80% may offer beneficial biomechanical effects compared to solid Ti or PEEK cages in lumbar interbody fusion.^{168,169} Preclinical large animal studies have demonstrated good biocompatibility and osteointegration of 3D-printed pTi cages.^{131,170–172} For instance, these implants have shown superior push-out strength compared to PEEK or allograft materials in a preclinical animal study.¹³¹ Notably, in an ovine model, 3D-printed porous Ti interbody cages were associated with enhanced bone ingrowth, significantly reduced range of motion, and improved construct stiffness compared to PEEK and plasma sprayed pTi-coated PEEK for lumbar fusion.¹⁷⁰ Furthermore, the absence of an interface between different materials with different moduli solid 3D-printed metal cages is theorised to reduce the risk of delamination.¹⁷⁰ Initial clinical evidence indicates that porous Ti cages yield superior radiographic and clinical outcomes compared to PEEK cages, underscoring their successful translation from preclinical to clinical settings.^{156,173,174} Fujibayashi *et al.*¹⁵⁶ implanted porous bioactive Ti cages with autograft in a TLIF technique in five patients, achieving successful bony fusion within six months and a significant improvement in clinical parameters in all cases. Subsidence rates of 6.7% per surgery and 3.4% per implant for 3D-printed Ti cage

(Modulus; NuVasive, San Diego, CA) implanted *via* minimally invasive transposas XLIF were reported by Krafft *et al.*¹⁷³ which are lower compared to previously reported subsidence rates of PEEK cages implanted *via* minimally invasive XLIF (10.0 to 16.1%).^{120,175,176} By comparing Ti-coated PEEK cages (ProSpace XP; Aesculap AG, Tuttlingen, Germany; pore size, 50–200 μm ; mean porosity, 37.3%; elastic modulus, 4.6 GPa) in 34 patients with 3D porous Ti alloy cages (Tritanium PL; Stryker, Kalamazoo, MI; pore size, 100–700 μm ; mean porosity, 60%; elastic modulus, 6.2 GPa) in 29 patients, Makino *et al.*¹⁷⁴ observed similar fusion rates and patient-reported outcomes. However, the Ti-coated PEEK cage group exhibited a higher incidence and severity of postoperative vertebral endplate cyst formation. Thus, long-term prospective randomised trials comparing these with conventional cage materials and designs are necessary to confirm the radiographic and clinical superiority of the promising short-term results associated with porous Ti cages.¹⁶⁷

3.3.2 PEEK cages. Due to their inert nature in biological environments, ease of processing, and ability to provide mechanical support, many non-degradable synthetic polymers have been extensively investigated for biomedical applications.¹⁷⁷ While synthetic polymers generally resist hydrolytic, oxidative, and other degradation mechanisms, PEEK stands out as a semi-crystalline thermoplastic with exceptional mechanical and chemical resistance properties. These characteristics confer resistance to post-irradiation degradation, allowing PEEK to be sterilised by gamma and e-beam irradiation while maintaining its mechanical strength over extended periods in dynamic environments.¹⁷⁷

PEEK's elastic modulus is nearly identical to human cortical bone's modulus, particularly when reinforced using carbon, which might lead to advantages in load sharing and stress distribution and, thereby, reduce cage subsidence.⁵⁰ Additionally, compared to Ti, PEEK has shown significantly lower stress compression strength (2.5 times weaker).¹⁷⁸ Concerns of synovitis and the lymphatic spread of non-absorbable polymer debris has been raised in early studies.^{179–181} However, multiple subsequent studies on local and systemic toxicity showed that PEEK does not illicit adverse tissue reactions.^{182–185} After its first development in 1978 it was approved a year later by the FDA for intervertebral spacers¹²⁴ and its good mechanical properties and chemical resistance resulted in its wide use.⁵³ Particularly, due to its radiolucency, less artefacts on computed tomography (CT), and MRI scans occur, which allow for more appropriate visualisation of possible migration (*i.e.*, radiolucency) and the bony fusion status.^{125,178} However, lower support for osteogenic tissue and lower level of bone integration has been reported for PEEK compared to Ti.⁵⁰ For instance, single-level interbody fusion rates of only 71% have been observed with PEEK cages augmented with autograft in ovine models.¹⁸⁶ This reduced fusion rate is partly attributed to the formation of a fibrous layer at the bone–implant interface, which is inhibited due to PEEK's chemically inert and hydrophobic surface.¹⁸⁷ For instance often peri-implant fibrous tissue is formed on the bone–



implant interface, potentially due to a hydrophobic PEEK surface that is associated with production of inflammatory chemokines¹⁸⁸ and inhibitory effects on osteoblastic differentiation of progenitor cells.⁶⁰ Eventually this reduced capacity for osteointegration and achieving a solid bone-cage fusion increases the risk of long-term sequelae such as micromotion, which in turn is associated with implant failure and pseudarthrosis.^{189,190}

Notably, clinical studies reported no difference in clinical outcomes between PEEK, Ti, and carbon fibre cages.^{50,191,192} Thus, recommendations for the most effective interbody fusion material are limited due to the similarity in clinical and radiographic outcomes among these materials. Combined Ti/PEEK spinal fusion cages have shown comparable safety, efficacy, fusion rates, and clinical outcomes to standard PEEK cages.¹⁹³ Therefore, PEEK cages are primarily used when their radiolucent properties are essential, such as in cases requiring radiotherapy or following spinal infections.

3.3.2.1 PEEK composites and surface modifications. To enhance the biological interaction of otherwise inert materials and promote tissue integration, various additives and surface modification techniques are employed. For instance, adding metals like Ti to PEEK has been shown to improve its performance in spinal fusion applications.¹⁹⁴ Methods to create Ti-PEEK composites include compression moulding to construct Ti endplates around a PEEK core, or surface coatings *via* techniques such as e-beam deposition, plasma spray coating, or direct metal laser sintering.⁵² Surface coating of PEEK with a pure Ti layer using e-beam deposition has demonstrated improved cell survival, higher alkaline phosphatase activity, and a greater bone-in-contact ratio compared to uncoated PEEK implants.⁵³ However, plasma spraying and vapor deposition methods for coating PEEK cages can lead to surface cracking due to weak interfaces, potentially impacting implant performance.^{59–61} Plasma-sprayed Ti creates a rough and porous surface that may enhance osteointegration while providing X-ray translucency and reducing stress shielding. This process of rough surface coating potentially inhibits implant migration while its porous texture provides optimal support for osteointegration.^{130,195–197} Ti-coated PEEK (Plasmapore^{XP}®; Aesculap AG, Tuttlingen, Germany) showed increased early bone formation activity and improved bone-implant interface compared to PEEK alone (PEEK-OptimaTM; Invibio, Lancashire, UK) *in vitro* as well as *in vivo* when implanted orthotopically.⁵⁴ However, plasma spraying results in a relatively thick Ti layer (ranging from 13.4 to 70 µm) which may raise concerns about delamination^{198,199} and denaturation of PEEK due to the high temperatures used in the coating process. Delamination can result in wear debris, which may cause local inflammatory reactions, although specific particle concentration thresholds for adverse postoperative effects are not yet defined.²⁰⁰ Various animal and clinical studies reported local inflammatory reactions of Ti-related wear debris which may cause biological reactions in the human body^{201–203} but possible cut-off values for concen-

trations of these particles causing consequences in terms of postoperative complications are yet to be defined.²⁰⁰

Authors of smaller clinical trials conclude based on their results that Ti-coated PEEK-cages are safe and efficacious.^{55–57} Rickert *et al.*⁵⁷ observed identical clinical outcomes and a high rate of fusion (thin slice CT at three months and functional radiography at 12 months) in both groups of PEEK comparing to Ti-coated PEEK cages in a pilot trial of 40 patients. A prospective randomised trial including 60 patients with six and 12 months follow-up points for fusion rates (plain X-rays and CT scans) and clinical outcomes of PLIF surgery with Ti-coated PEEK cages (coated Wave®, Advanced Medical Technologies AG, Medtronic, Minneapolis, Minnesota, USA) *versus* uncoated PEEK cages (Wave®, Advanced Medical Technologies AG) performed for 24 months (visual analogue scale, VAS; Oswestry Disability Index score, ODI; EQ-5D) showed similar clinical and radiological results.²⁰⁴ A vacuum plasma spray technique for coating of the upper and lower surfaces of the cages was used, melting pure Ti particles in a hot plasma beam and vaporising the droplets onto the PEEK cage which resulted in thickness of the Ti coating of 25–160 µm and a micro-roughness of at least 50 µm.²⁰⁴ Another multicentre, randomised study with 149 patients (PLIF and TLIF) followed up for 12 months showed no difference in spinal fusion rate.⁵⁸ However, Ti-coated PEEK cages compared to PEEK cages were associated with better bone fusion at six months after surgery and the authors claim thereby an earlier return to work for the patients.⁵⁸

Alternative surface coatings include CaP, HA, metallic oxides, or polymers.^{205–207} Methods for applying these coatings include drop-casting, dipping, spraying, and polyelectrolytic deposition.²⁰⁵ Extensive research on its challenges and approaches²⁰⁸ and release kinetics as well as methods of encapsulation and protection of incorporated factors²⁰⁹ have been published. Additionally, release of incorporated factors may occur in response to certain local stimuli after implantation of the device such as enzymes (*e.g.*, matrix metalloproteinases) or pH changes, as well as external stimuli such as ultrasound as described in detail by Qu *et al.*²¹⁰ While these types of coating are mainly achieved by using plasma spraying, electrochemical deposition, the sol-gel technique, and high-velocity suspension flame-spraying, their detailed application processes are described elsewhere.²¹¹

Hydroxyapatite coating on PEEK can be applied through various methods such as plasma spray, cold spray, and aerosol deposition. *In vitro* studies indicate that such application is associated with improved cell viability, adhesion, proliferation, and alkaline phosphatase activity.^{212–214} Although no published human clinical trials specifically address HA-coated PEEK cages, a recent multicentre, single-arm, prospective study assessed the safety and osteoconductivity of a silver-HA-coated (Ag-HA coating thickness: 2 mm, KYOCERA, Kyoto, Japan) Ti intervertebral cage (ResitageTM, Kyocera, Kyoto) used in PLIF or TLIF. The study, comprising 55 participants with six- and 12-month follow-up points for fusion rates (evaluated through lateral dynamic X-rays and multidetector-row CT



scans), demonstrated comparable clinical and radiological outcomes. Nevertheless, further investigations, including a subsequent ongoing study (UMIN 000039964), are warranted to evaluate the antimicrobial and osteoconductive effectiveness of Ag-HA coatings against a control group, employing larger sample sizes to comprehensively assess the safety of Ag. Despite the absence of specific human trials, small animal studies with HA coating alone suggest increased peri-implant bone formation and biomechanically relevant bone implant-contact.^{212,215,216} Moreover, large animal studies have reported enhanced osteointegration and pull-out strength for plasma-sprayed HA coating on PEEK and carbon fibre-reinforced PEEK for implants placed in the pelvis.²¹⁷ Although HA coatings naturally degrade in the body, contributing to their bioactivity, excessive degradation over a long-term implantation period could lead to adverse effects.²¹⁸ This raises unresolved concerns regarding the efficacy and safety of HA coatings. Further research is essential to better understand and address the nuances of HA degradation, ensuring its optimal functionality throughout extended periods of implantation.

Recently, simple and cost-effective methods were developed such as a novel bioactive sol-gel TiO₂ coating involving sandblasting and acid treatment offering increased PEEK bone-bonding ability without affecting mechanical behaviour.²¹⁹ Thereby, the mechanical behaviour, *i.e.* the elastic modulus, is not altered because the surface coating does not exceed the glass transition temperature of PEEK.^{125,220} The bonding strength of the TiO₂ gel layer to the PEEK was successfully evaluated with a modified ISO 2409 tape test.²²⁰ These results validated Pátsi *et al.*²²¹ who suggested that sol-gel-derived layers were sufficient for their use as an implant coating material because of the bonding strength (>24 MPa). Sandblasting of the TiO₂ particles and the sol-gel layer results in a strong chemical bonding layer between the two as well as a beneficial nano-scale roughness.²²² Similar nano-scale roughness on neat PEEK was produced by Khoury *et al.*²²³ utilising a neutral atom beam technique to improve bone apposition in a rat calvarial model. Sol-gel-derived TiO₂-coated bioactive PEEK implants demonstrated better fusion rates and bone-bonding ability compared to the uncoated PEEK implant in a canine anterior cervical fusion model.²²² Further, the maximum temperature of 80 °C did not adversely affect the mechanical properties of PEEK.²²² *In vitro* and preclinical *in vivo* studies of cell activity and osteointegration have demonstrated improved cell attachment, greater bone volume and increased bone deposition and remodelling, fabricated by powder mixing and compression moulding methods,²²⁴ when comparing n-TiO₂ nanoparticle/PEEK composite, against PEEK polymer control.²²⁵

Therefore, future implant structures and design may want to improve material chemistry and architecture as well as further optimise surfaces allowing for more efficient bone integration. For instance, PEEK composites, *e.g.* incorporating additives such as HA, or surface modifications may further improve the attractiveness of the biocompatible, inert, and inherently strong PEEK.

3.3.3 Alternative non-resorbable materials

3.3.3.1 Tantalum (*trabecular metal*). Comparable to Ti, Ta is a metal which has been used in orthopaedic surgery since the 1940s²²⁶ and is particularly noted for its porous structure, which closely resembles the cancellous bone. With a porosity ranging between 75% and 85%, porous Ta supports cell proliferation and osteogenesis of human osteoblasts.²²⁷ Its low elastic modulus closely mimics that of subchondral bone, while its high coefficient of friction provides excellent primary stability.²²⁸ For in depth overview of porous Ta in spinal surgery please consider the review of Hanc *et al.*²²⁸ Despite its favourable mechanical properties, Ta's biological inertness limits its ability to bond with bone. However, the open-pore structure may still promote vascularisation and bone remodelling. Studies have shown mixed results regarding its clinical efficacy.²²⁹

Bone marrow (BM)-derived mesenchymal stem cells (BM-MSCs) cultured on porous Ta implant and implanted in the intervertebral space of rabbits did not show superior lumbar interbody fusion rates compared to ABG alone after 12 months.²³⁰ Also, large preclinical animal studies indicate limited bone in growth of 8% to 15% into porous Ta implants at 12 weeks after implantation.^{231,232} A small clinical trial report of 40 patients that received anterior, posterior, or transforaminal lumbar 360° interbody fusion including a Ta cage without additional ABG showed a fair fusion rate of 68%.²³³ However, higher rates of subsidence²³⁴ and excessive artefacts on postoperative MRI and computed tomographic imaging are major concerns limiting the application of Ta implants.²³⁵

3.3.3.2 Silicon nitride (Si₃N₄). Silicon nitride (Si₃N₄ implants, ceramic material) has recently attracted attention for its use in interbody fusion. Si₃N₄ is a hydrophilic, negatively charged ceramic with superior compressive strength compared to PEEK and Ti.²³⁶ Its surface charges enhance the adhesion of cells and proteins, which may facilitate better osteointegration.²³⁷ Moreover, Si₃N₄ implants tend to produce fewer artefacts on advanced imaging compared to other materials²³⁸ and exhibit increased resistance to bacterial biofilm formation.²³⁹ A two-year industry-sponsored randomized controlled trial comparing PEEK and Si₃N₄ in the TLIF technique found insufficient evidence to establish Si₃N₄'s non-inferiority to PEEK. Nevertheless, both materials showed favourable clinical improvements.²⁴⁰ Similarly, a single-blinded randomised controlled trial comparing PEEK to Si₃N₄ in anterior cervical discectomy and fusion (ACDF) reported comparable clinical outcomes and fusing rates at 24 months for both materials.²⁴¹ Additionally, a multicentre retrospective study found Si₃N₄ to have comparable pain reduction and reoperation rates to other materials used in various lumbar spinal fusion procedure.²⁴² However, further prospective long-term studies are necessary to evaluate Si₃N₄'s effectiveness in facilitating lumbar spinal fusion compared to conventional materials.^{237,239} Future research should also confirm the antimicrobial properties attributed to Si₃N₄. Current evidence suggests that Si₃N₄ does not significantly differ from conventional PEEK cages in terms of bony fusion outcomes.



3.3.3.3 *Nitinol*. Nitinol, discovered in 1962 by William J. Buehler and later industrially utilised,²⁴³ has garnered interest for its unique properties. In the 1980s, its rheological similarity to biological tissues was noted following the development of specialised NiTi-based alloys.²⁴⁴ Details of material properties and characteristics are reviewed elsewhere.²⁴⁵ In brief, NiTi belongs to the family of Ti based intermetallic materials containing almost equal amount of Ni and Ti. Thermoelastic martensitic transformation properties allow for shape memory and superelastic characteristics.^{246,247} Its transformation temperature (36.85 °C) which is close to body temperature as well as low elastic modulus similar to bone and compressive strength greater than human bone make its use for biomedical implant applications appealing.^{248,249} Noteworthy, Ni is a toxic element with (contact) allergy reported for up to 20% of the female European population²⁵⁰ due to the corrosion of NiTi in physiological environments Ni and Ti are released.²⁵¹ To improve corrosion resistance self-propagating high-temperature synthesis (SHS) is used to obtain porous NiTi alloys (PTN). Surface layers of PTN serve as a protective barrier in physiological environments, improving corrosion resistance.²⁵² For instance, porous NiTi particles from the Actipore PLFx (Biorthex Inc., Montreal, QC, Canada), produced using SHS, were implanted in the spinal canal on the dura mater of rabbits.¹⁰⁴ Follow-up studies showed no particles or abnormalities in the organs, mild inflammation confined to the epidural space, and similar results to a control group of Ti implants, suggesting that NiTi fabricated with SHS may be a safe option for intervertebral fusion devices.¹⁰⁴ Ungrafted cylindrical NiTi cages (Actipore™; Biorthex Inc., Montreal, QC, Canada) demonstrated favourable outcomes compared to conventional TiAlV cages (BAK™ cages; Sulzer Spine-Tech, Inc., Minneapolis, MN) packed with autologous bone, showing superior bone integration and apposition capacities in an ovine PLIF model.²⁵³ A retrospective cohort study of 41 patients receiving the porous NiTi cage (Actipore™; Biorthex Inc., Montreal, QC, Canada) reported a 98% complete fusion rate on radiography at one year.²⁵⁴ Further investigations on corrosion fatigue behaviours of porous NiTi alloys and prospective studies comparing to conventional interbody devices are necessary to accomplish a complete and systematic understanding of PTN.

4. Bone grafts to facilitate spinal fusion

4.1 Autograft

Autologous bone graft, harvested either from the iliac crest or local bone excised during spinal decompression, remains as the established gold standard for promoting bone regeneration in lumbar spinal fusion surgery.^{38,255,256} Despite the substantiated efficacy of iliac crest ABG demonstrated in numerous studies, concerns regarding associated morbidities, such as donor site pain, wound complications, prolonged operation time, and long-term functional impairment, have been

reported.^{257–261} Importantly, volume loss of up to ±35% during the first year after implantation in the posterolateral spine is described due to the resorption and remodelling of the autograft.^{262–264} However, a preclinical large animal study employing a goat instrumental posterolateral fusion model observed superior fusion potential for autograft compared to donor allograft and synthetic bone substitutes.²⁶⁵ The recognised advantages of ABG, including its lower cost and absence of disease transmission risk, further underscore its significance.³⁰ Recent studies have shifted focus towards local ABG retrieved from the vertebral segment, as extensively reviewed by others.²⁶⁶ Specifically, bone dust collected during spinal decompression has shown the capability to release growth factors and cytokines with anabolic effects on human osteoblasts.³⁷ Moreover, studies have demonstrated a superior osteogenic potential of vertebral body BM-MSc compared to iliac crest BM-MSc.²⁶⁷ Several commercially available bone graft collectors,²⁶⁸ such as the Bone Vac (Stryker®) (Supplement 1) or Marrow Cellution™ (Medtronic®), are currently marketed with the aim of reusing or collecting local bone (dust) or BM to induce spinal fusion. In a goat intertransverse processes fusion model, intraoperatively isolated BM-MSc with poly-L-lysine-enriched demineralised bone matrix (DBM) showed comparable bone fusion to ABG.

However, the ideal biomaterial for cell delivery remains unidentified.²⁶⁹ For instance, delivery within a poly(lactic-co-glycolic acid) (PLGA)/biphasic calcium phosphate (BCP)/collagen graft, as opposed to a PLGA/HA/collagen composite,²⁷⁰ or BM-MSc within mineralised silk scaffold, as compared to a non-mineralised scaffold, induced greater bone formation.²⁷¹ Importantly, human clinical studies focusing on fusion/pseudarthrosis rates and clinical outcomes while comparing different ABG sources for spinal interbody and posterolateral fusion are scarce.²⁷² Therefore, the improvement of bone graft harvesting approaches, and the development of bone graft substitutes emerge as fundamental components of future research endeavours to enhance the success of spinal fusion surgeries. Table 1 provides a summary of the advantages and disadvantages, along with osteoconductive, osteogenic and osteoinductive properties of ABG and bone graft substitutes.

4.2 Bone graft substitutes

The escalating incidence of spinal surgeries, coupled with the growing need for larger bone graft volumes, has driven the extension of autograft applications to promote effective bony healing.²⁷³ This surge in demand has spurred the development of diverse bone graft substitutes, including allografts and synthetic alternatives. Albeit a multitude of choices, allografts in comparison to autografts, exhibit diminished osteoinductive capacity, lack osteoprogenitor cells, pose risks of immune reactions, and carry a small but potential risk of disease transmission.^{274–276} Consequently, the reliance on synthetic bone graft substitutes has become prominent, with the United Kingdom alone offering 59 different products in the market.²⁷⁷ These substitutes are utilised in over a third of bone graft surgeries,²⁷⁸ underscoring their crucial role in miti-



Table 1 Advantages and disadvantages along with osteoconductive, osteogenic and osteoinductive properties of autologous bone graft and bone graft substitutes. Partially created with BioRender.com. Table adapted from ref. 288 with permission from Elsevier, copyright (2021). Table adapted from ref. 289 with permission from Taylor & Francis, copyright (2012)

	Autologous bone graft	Allogenic bone graft	Synthetic bone material	Growth factors and bio-active molecules
Form	Cancellous (trabecular) and cortical	Cancellous (trabecular), cortical and demineralised bone matrix (DBM)	Pellets, powders, mixable injectable forms, mouldable semi-solid cement, granules, and various implantable solid forms: blocks, cubes, wedges, cylinders	Molecular carriers to deliver and hold to their intended targets in bone. Structural (e.g., synthetic polymers or calcium ceramics) or non-structural, e.g., BMP-saturated collagen sponges
Advantages	Gold standard as it is osteoconductive, osteoinductive and osteogenic ^{290,291}	No second surgical site (lower risk of infection and no additional pain) ²⁹²	Many options for bone substitute materials, custom scaffolds (3D-printed and injectable) ^{293,294}	Both osteoinductive and osteoconductive properties ²⁸⁹
Disadvantages	Additional surgical site increases the risk of infection and limits the amount of available graft material ²⁸⁵	Risk of disease transmission or adverse immune response ^{274,295}	Deficiency of growth factors to promote bone growth ²⁹⁶	No long-term studies, inflammatory complications with off-label applications, very expensive ^{28,28,297}
Osteoconductive	✓	✓	✓	✗
Osteoinductive	✓	✓	✗	✓
Osteogenic	✓	✗	✗	✗
Specification	—	Allogenic Spongiosa	Tricalcium-phosphate	rhBMPs
Costs in US-Dollar (\$)	Estimates report average (surgical) costs of 338–1000 \$ depending on the size of the areas to be transplanted ²⁸⁸	Cancellous, freeze-dried bone: ²⁹⁸ 376 \$ per 30 cm ³ MinerOss cancellous bone (BioHorizons): 464 \$ per cm ³ Osteoceil (NiuVasive): 472 \$ per cm ³	Demineralised bone matrix Grafton/ Allomatrix: ²⁹⁸ 726–1225 \$ per 10 mL DBX (Synthes)/ Dynagraft: 200–4500 \$	OP-1 (Stryker) USD 5000; Infuse (Medtronic-Sofamor Danek) USD 3500–4900; 3500–5000 \$
			Biphasic calcium-phosphate NovaBone (Osteogenics): 410 \$ per cm ³	
			Calcium-phosphate CopiOs (Zimmer Spine): 1520 \$ per 10 mL	
			Calcium-sulphate Osteoset (Wright Medical Technology): 655 \$ per 10 mL	



gating complications associated with ABG and facilitating bony fusion, especially in complex, multi-segmental spine surgeries. Notably, synthetic bone graft substitutes comprise demineralised bone matrix (allograft) and various ceramic and bioglass formulations, alongside commercially available growth factor products. These alternatives contribute to the armamentarium of available options for enhancing spinal fusion.

4.2.1 Allografts. Demineralised bone matrix is a cortical allograft bone that undergoes acid-decalcification and sterilisation, emerging as a supplementary or alternative option to ABG since its introduction in 1991. The mineralised component of bone is selectively removed through a mild acid-extraction process pioneered by Urist in 1965,²⁷⁹ resulting in a composite product of collagen, non-collagenous proteins and growth factors.^{280,281} Although its mechanical strength is significantly reduced during demineralisation and sterilisation, the trabecular structure is retained, along with some growth factors, preserving its osteoconductive and partially osteoinductive capacity.²⁸² Due to its biological and structural properties, DBM is considered a hybrid material. In various commercially available products, DBM is used in combination with autograft, allograft, bone marrow aspirate, collagen-ceramic composites, polymer-ceramic composites, or growth factors.²⁸³ Fusion rates of 94%, comparable to those of ABG alone, have been observed in lumbar fusion using DBM as graft expander.²⁸⁴ A comprehensive review of the efficacy of DBM in spinal fusion has been published by others.^{281,285}

In a more challenging elderly population undergoing posterolateral interbody fusion, the combination of DBM with BM aspirate yielded successful fusion in 84% of cases.²⁸⁶ However, using allograft alone as bone substitute in posterolateral fusion is not sufficient, with average fusion rates as low as 52% reported.²⁷³ The main underlying reason for slower and less complete allograft incorporation into native bone is particularly related to lack of vascularisation,^{274,287} emphasising the substantial need for further investment in synthetic bone grafts.

4.2.2 Synthetic bone grafts. Traditionally, synthetic bone grafts investigated for spine surgery are CaP-based synthetic ceramics and bioactive glass.^{277,299} The mineralised inorganic phase of bone encompassing osteoconductive, biocompatible, and bone-bonding properties, bears similarity to the microstructure of ceramic composites.³⁰⁰ These inert substances pose no risk of disease transmission and have a long storage life.³⁰¹ Consequently, the biocompatibility, osteoconductivity, and strong mechanical properties of ceramic-based substitutes are crucial features stemming from their chemical resemblance to the inorganic phase of bone, elucidating their relevant role in bone graft replacement.^{28,287} However, their limitations regarding osteogenic and osteoinductive capabilities, slow degradation, and mechanically brittle and stiff behaviour are less advantageous.^{282,302} Typically, mono-, bi- and tri-calcium phosphate and HA are employed alone or combined with collagen, polymers, or other carrier materials to create cement.^{303,304}

BoneSave (Stryker), consisting of 80% Tri-Calcium Phosphate (TCP) and 20% HA provides an effective, biocompatible matrix. Clinical outcomes from the early 2000s showed a 57% fusion rate in a retrospective cohort of 45 patients undergoing PLIF, comparable to traditional allograft and autograft techniques.^{305,306} Recent third-generation bioactive ceramics have further explored the concept of standalone bone graft substitutes. Biphasic calcium phosphate (BCP) bone graft (MagnetOs; Kuros Biosciences), composed of 65–75% TCP ($\text{Ca}_3(\text{PO}_4)_2$) and 25–35% HA ($\text{Ca}_{10}(\text{PO}_4)_6(\text{OH})_2$), exhibited similar performance in posterolateral spinal fusion in rabbits when used as autograft extender compared to autograft alone.³⁰⁷ AttraX (NuVasive) has also demonstrated success in animal models and clinical trials. In a recent clinical trial, 100 patients undergoing PLIF received AttraX putty and autografts on contralateral sides. At the one-year follow up, the bioactive ceramic demonstrated a 55% fusion rate compared to a 52% fusion rate for the autograft.^{308,309} The fusion rate at the two-year follow up significantly increased to 70% and 68% respectively, with no difference between the grafts.³¹⁰

Additionally,³¹¹ observed equivalent performance in achieving spinal fusion in a large animal study of calcium phosphate with submicron topography compared to autograft. While fusion rates of up to 87% are reported for calcium phosphate compared to iliac crest bone graft (ICBG) rates of up to 90% after 33 months, it is concurrently associated with inflammation and wound healing complications in up to 51% of patients.^{312,313} Fusion rates of up to 100% after posterolateral fusion are observed for beta-TCP (β -TCP) in combination with autograft or allograft at three years follow-up.³¹⁴ Hyperelastic Bone® is a 3D-printable HA-based material that, in combination with rhBMP-2, showed promising fusion rates, although when used alone, a sufficient fusion rate to justify clinical testing was not achieved.³¹⁵ However, it is necessary to consider that bone and ceramic substitutes have similar density on plain radiographs and CT scans, potentially mimicking true bone fusion and thereby impairing the interpretation of fusion rates.

Bioactive glass, including 45S5 bioactive glass (*i.e.*, Bioglass) developed by Hench and colleagues in the 1970s³¹⁶ as a bone graft substitute material,²⁹⁹ stimulates activity of osteogenic cells *in vitro* by releasing ionic dissolution products (osteostimulation).^{317–319} In simulated body fluid, bioactive glass elicits deposition of a crystalline calcium phosphate surface layer,^{320,321} which is associated with osteoconduction and strong bone-bonding *in vivo*.^{148,322} Advanced laboratory techniques, including additive manufacturing, allowed for processing into 3D scaffolds, making it a promising synthetic bone graft substitute candidate. The increased porosity improved the osteoinduction and resorption while relevantly decreasing its mechanical strength, as shown in preclinical trials.³²³ However, in a preclinical large animal study of posterolateral fusion, no promotion of spinal fusion has been observed for 45S5 Bioglass in BG and TCP/BG grafts.³²⁴ Ultimately, inferior fusion results relative to autograft controls are observed because bioactive glass resorbs too rapidly before



bone formation can occur.³²⁵ Thus, osteostimulative bioglass in its current texture and biological composition may have limited relevance as bone graft material in spinal fusion. Moreover, preclinical animal studies indicate an inflammatory foreign body reaction around bioglass.^{326–328} Nonetheless, the authors are confident that ongoing developments in additive manufacturing will support and improve the application possibilities of bioglass while stressing its inherently suitable osteogenic properties as a bone substitute.

4.2.3 Growth factors and bio-active molecules. The differentiation, maturation, and proliferation of MSCs into osteogenic cells are substantially influenced by growth factors (Fig. 7). Potential growth factor candidates include bone morphogenetic proteins (BMPs), transforming growth factor- β , and platelet-derived growth factor. In this review, we focus on BMPs, initially described by Marshal Urist in 1965,²⁷⁹ later identified as soluble members of the transforming growth factor- β superfamily.^{261,329} The stimulation of bone healing by BMPs,³³⁰ particularly rhBMP-2 (INFUSE, Medtronic) and rhBMP-7 (OP-1 putty, Stryker Biotech) in the early 2000s, has been demonstrated as safe and efficacious in non-union of long bones.³³¹ Strong interactions with bone-like mineral sub-

strates have also been shown for multiple growth factors, including BMP-2, insulin-like growth factor-1 (IGF-1) and TGF- β .^{332–337} In non-unions, rhBMP-7 has been shown to have an efficacy similar to bone grafting, and fewer complications.³³⁸ However, large, prospective, randomised, controlled multicentre clinical trials investigating OP-1 for its use in lumbar spinal fusion showed superior results for autograft *versus* OP-1 on plain films at 2-year follow-up and CT-scan results at 3 years,^{339,340} leading to FDA rejection of Pre-Market Approval (PMA) of OP-1 in April 2009.³⁴¹ This biological enhancer of bone formation is currently not commercially available.³⁴² Additionally, rhBMP-7 is associated with high costs and unknown carcinogenic potential.³⁴³ Thus, rhBMP-2 is the most clinically relevant growth factor. Extensive reviews of additionally relevant growth factors and signalling molecules for migration and differentiation of bone forming cells are published by others.^{344,345}

RhBMP-2 achieved FDA approval for single-level ALIF with a specific Ti cage in 2002. Any other application is considered off-label or 'physician-directed application'. Its use in spinal fusion surgery increased from 0.7% in 2002 to 20% in 2006 and Medtronic reports nearly \$400 million dollars in sales in




Fig. 7 Working mechanism of bone morphogenetic proteins in bone regeneration. Figure created with BioRender.com.



2012.³⁴⁶ However, due to serious complications including inflammation and pain associated with supraphysiologic dosing and off-label use, the clinical use of rhBMP-2 has drastically decreased.^{297,347} Nonetheless, rhBMP-2 is an FDA-approved bone graft substitute for spine fusion, used in combination with a type I collagen sponge as a carrier and commercially available as an additional substrate with high fusion rates without autograft bone or bone graft extenders.^{346,348,349} The landmark study of rhBMP-2 published by Burkus *et al.*³⁵⁰ demonstrated that patients treated with rhBMP-2 with a Lumbar Tapered Fusion Device (LT-CAGE, Medtronic Sofamor Danek, Memphis, TN, USA) had superior fusion rates and functional outcome compared to patients treated with ICBG. Particularly, they observed in a follow-up study including the combination of datasets from two additional clinical trials superior 24-months fusion rates for rhBMP-2 (94.4%) compared to autograft (89.4%).³⁵¹ These beneficial radiographic and clinical outcomes have been challenged in multiple reports and trials reporting significant endplate resorption, osteolysis, and graft subsidence with rhBMP-2 used in ALIF.^{352–354} Higher reoperation rates in patients treated with rhBMP-2 has also been attributed to graft subsidence complications.³⁵⁵ Further, increased rates of retrograde ejaculation of 6–7% are reported in ALIF with rhBMP-2^{356,357} compared to baseline rates of less than 1% in patients with no rhBMP-2 application.^{358–360}

The use of rhBMP-2 in PLIF has been evaluated in two prospective randomised multicentre trials showed. In the first trial, a dose of 20 mg per side resulted in a higher fusion rate compared to iliac crest autograft alone (100% vs. 40%). In the second study, a higher dose of rhBMP-2 (AMPLIFY rhBMP-2 Matrix; Medtronic Sofamor Danek) was used, showing once again higher fusion rates relative to autograft (96% versus 89%) at the 2-year follow-up ($p = 0.014$). While clinical outcomes were similar between the two groups, the autograft group experienced significantly higher reoperation rates (16% vs. 8%, $p = 0.015$), and at two-year follow-up, 60% reported donor site iliac crest pain.³⁶¹ However, a retrospective review involving 130 patients undergoing PLIF with rhBMP-2 reported a reoperation rate of 4.6% due to sterile seromas.³⁶² Concerns regarding these complications led to the FDA rejecting Medtronic's application for the use of a higher-dose rhBMP-2 (AMPLIFY) in PLIF in March 2011. In summary, despite the relatively low absolute morbidity risk associated with the rhBMP-2 use in PLIF, which primarily involves higher rates of ectopic bone formation (EBF), a meta-analysis suggests that rhBMP-2 increases the likelihood of successful fusion without a clinically relevant reduction in pain for up to 24 months.³⁶³

The application of RhBMP-2 in PLIF as a fusion-inducing agent applied within intervertebral cages has demonstrated superior fusion rates compared to autograft. However, this approach is associated with relevant EBF, resulting in statistically significant extradiscal bone formation. Importantly, this increased EBF has not been correlated with clinical symptoms.³⁶⁴ Reports on the incidence of asymptomatic EBF are inconclusive, with rates ranging from very low to high.^{365–368}

The off-label use of rhBMP-2 in TLIF, combined with allograft or autograft,^{369,370} has shown good fusion rates with improvements in clinical systems. However, it is noteworthy that there are no available prospective randomised studies on this application. Complications associated with rhBMP-2 use in TLIF procedures have been reported in various case series and reports.^{45,371,372} Notably, postoperative radiculitis has been described in up to 20% of cases,³⁷¹ along with delayed neural compression due to symptomatic EBF,⁴⁵ and vertebral osteolysis in the range of 5.8% to 7.4%.^{371,372} In summary, the use of rhBMP-2 may be considered in PLIF when autograft is unavailable or harvesting is rejected by the patient.³⁴¹ However, caution is advised in PLIF and TLIF procedures due to concerns about EBF and potential neurological compromise.³⁶³

The delivery of pluripotent MSCs or growth factors represents a novel therapeutic approach aimed at stimulating bone deposition and amplifying fusion directly, potentially as a component of biodegradable scaffold material.^{373–375} In a preclinical large animal thoracic fusion study, superior histological and biomechanical fusion outcomes were observed when rhBMP-2 was loaded onto collagen-coated medical-grade polycaprolactone TCP (mPCL-TCP) scaffolds compared to ABG.³⁷⁶ Recognising the dose dependent response of rhBMP-2 on bone formation, it remains a potent agent in fostering bone formation while avoiding osteolytic outcomes.³⁷⁷ Additionally, rhBMP-2 may serve as template substrate to improve the binding of HA minerals, fostering bone healing and regeneration.^{332,337} More recently, an *in vitro* study suggests that achieving sufficient release rates of rhBMP-2 over a 2–4 weeks period is crucial for maximising angiogenesis and osteogenesis, essential components for successful bone regeneration.³⁷⁸

Incorporating growth factors into tailored bioresorbable implants with tuneable release is feasible³⁷⁹ and likely associated with accelerating tissue regeneration by matching the spatiotemporal demand.³⁸⁰ However, the design and manufacturing process of suitable delivery vehicles pose challenges, and dosing remains an issue.³⁷³ Currently, a commercially available delivery system for BMPs involves collagen sponges soaked in BMP at concentrations significantly higher than physiologically found in the human body. The effects of large bolus release are still under debate, and sponge-based BMP delivery systems, reliant on absorption into the sponge, make controlled delivery difficult to achieve. Initial reports suggest osteolysis of surrounding bone, promoting implant subsidence, swelling of surrounding soft tissue, and EBF. Future research explore alternative physiological and biocompatible carriers for BMPs, such as OSTEOGROW, derived from blood coagulum, aiming to address current challenges and improve outcomes in bone regeneration.³⁸¹

5. Conclusions and outlook

The growing prevalence of interbody spinal fusion, particularly among patients aged 75 and above, presents a looming chal-



lenge for global healthcare systems.³ Despite notable advancements in surgical techniques, biomaterials and spinal implants, the incidence of pseudarthrosis in over 10% of patients³⁸² presents significant hurdles, manifesting in poorer patient-reported outcomes, heightened demand for revision procedures, and elevated healthcare expenditures.^{383–385}

The landscape of interbody devices has undergone transformations, with modifications in Ti and PEEK devices incorporating diverse surface coatings and modifications. However, their efficacy lacks comprehensive validation from preclinical and clinical studies. A notable development has been the advent of 3D-printed Polyetherketoneketone (PEKK), exemplified by the TETRAfuse 3D spinal interbody implants. Preliminary findings from preclinical trials indicate enhanced implant osteointegration and trabecular bone in-growth, promising a potential paradigm shift in spinal fusion technology.³⁸⁶ A PEKK nano-roughened surface with antibacterial properties, has shown potential in fusion within an ovine bone femoral defect model, addressing concerns related to surface delamination and inadequate bone apposition linked to traditional materials like PEEK and Ti-coated PEEK.³⁸⁷ The future trajectory of this innovative cage candidate hinges on insightful clinical studies.

Traditional reliance on the gold standard of ABGs has been tempered by associated morbidity and limited donor tissue availability, fostering the quest for alternatives. Encouragingly, multiple rabbit studies exploring combinations of porous HA/poly(lactic acid) (PLA) composites,³⁸⁸ silicate-substituted HA grafts,³⁸⁹ and HA/TCP grafts³⁹⁰ have exhibited radiographic outcomes comparable to or surpassing those achieved with ABG. These studies, validated for true inter-transverse process arthrodesis, hold promise in translational relevance to humans.³⁹¹ Synthetic ceramic scaffolds, acting as extenders or replacements for bone grafts, have shown efficacy in providing a highly porous 3D-structure conducive to improved cell migration and osteointegration. Novel modifications, such as coating DBM with poly-L-lysine, or DBM supplemented with TCP, as shown in studies with protein kinase C-binding protein (NEL)-like protein-1 (NELL-1),^{392,393} highlight the ongoing exploration of these materials as potential graft extenders, with future investigations poised to unveil their clinical efficacy.^{394–396}

The intersection of material science and engineering has given rise to novel biologic materials, including nanocomposites, 3D-printed materials, and various biologic composites.³⁹⁷ These innovations address inherent limitations in current bone graft substitutes.³⁹⁸ Notably, DBM and cancellous scaffolds can serve as carriers for allogeneic MSCs and bone-marrow derived osteoprogenitor cells, exemplified by cellular bone matrices (e.g., OsteoCel™, Nuvasive, Ca, USA). Preliminary outcomes, including fusion rates of up to 91.3%–92.3% in lumbar interbody fusion procedures with OsteoCel™ (Plus)™, demonstrate promise with low complication rates of less than 2%.^{399,400} The availability of various cellular bone matrices in the market necessitates future prospective studies to compare them to BMPs and ABGs for more conclusive

recommendations.^{401–403} Furthermore, integrating bioactive peptides with porous implants and materials has advanced the development of fusion extenders.⁴⁰⁴ Notably, P-15™, a synthetic polypeptide that facilitates osteogenic cell attachment by mimicking a domain of type I collagen^{405,406} has recently transitioned from dental applications to spinal use. I-FACTOR™ (Cerapedics, Inc., Westminster, CO), a proprietary composite of P-15 and anorganic bovine bone mineral (ABM),⁴⁰⁷ has shown promising outcomes in enhancing fusion and clinical results in patients undergoing ALIF for degenerative spine conditions.⁴⁰⁴ In PLIF procedures, I-FACTOR demonstrated efficacy similar to or better than autografts at both 6 and 12 months, with improvements in pain and function surpassing success criteria at all evaluated intervals.⁴⁰⁵ While conclusive findings for lumbar spine applications pose challenges, recent level III and IV studies suggest that ABM/P-15 may offer benefits for lumbar fusion.⁴⁰⁷

The culmination of successful 360° stabilisation and fusion hinges on the harmonious integration of spinal instrumentation, intervertebral body devices, and ABGs or bone graft substitutes. The advent of additive manufacturing has democratised medical device research and development, equipping laboratories with the tools to explore complex interbody cage designs that tailor geometry, porosity, and interconnectivity to achieve better biomimetic mechanical performance, osteogenic differentiation, and osteointegration in *in vivo* models. Surface topographic modifications, particularly, HA coatings, antibacterial elements, and mechanical roughening show great promise and contribute to the development of an inhabitable environment, fostering optimal conditions for cellular processes critical to successful fusion. As research endeavours unfold, the synergistic relationship between technology and biological materials holds the key to unlock transformative advancements in the field of lumbar spinal fusion. However, the trajectory towards safer and more efficacious procedures is contingent on collaborative efforts and innovative research, placing substantial emphasis on rigorous clinical validations. While *in vitro* and animal *in vivo* trials provide valuable insights, the translation of these findings into clinical practice necessitates robust clinical evidence. A concerted commitment to comprehensive clinical validations will be pivotal in ensuring that the promising developments witnessed in the laboratory setting translate into tangible benefits for patients undergoing spinal fusion procedures.

Author contributions

Giles M. Cheers: conceptualization, methodology, investigation, writing – original draft, visualization. Lucas P. Weimer: methodology, investigation, writing – review & editing, visualization. Carl Neuerburg: methodology, investigation, writing – review & editing. Jörg Arnholdt: methodology, investigation, writing – review & editing. Fabian Gilbert: methodology, investigation, writing – review & editing. Christoph Thorwächter: methodology, investigation, writing – review & editing. Boris



M. Holzapfel: methodology, investigation, resources, writing – review & editing, supervision. Susanne Mayer-Wagner: methodology, investigation, resources, writing – review & editing, supervision. Markus Laubach: conceptualization, methodology, writing – original draft, visualization, supervision, project administration.

Data availability

No primary research results, software or code have been included and no new data were generated or analysed as part of this review.

Conflicts of interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

Graphical abstract created with **BioRender.com**, scaffold created with nTop, Release 4.21.1, nTop Inc., <https://ntop.com>. We would like to thank Sara Mohr for her support in designing Fig. 1 and 7, which were created using **BioRender.com**. The authors gratefully acknowledge the support of the Alexander von Humboldt Foundation funding a Feodor Lynen Return Fellowship awarded to Markus Laubach.

References

- G. B. Andersson, *Lancet*, 1999, **354**, 581–585.
- B. I. Martin, S. K. Mirza, N. Spina, W. R. Spiker, B. Lawrence and D. S. Brodke, *Spine*, 2019, **55**, 369–376.
- V. J. Heck, K. Klug, T. Prasse, S. Oikonomidis, A. Klug, B. Himpe, P. Egenolf, M. Lenz, P. Eysel and M. J. Scheyerer, *Clin. Orthop. Relat. Res.*, 2023, **481**, 1610–1619.
- T. Mabud, J. Norden, A. Veeravagu, C. Swinney, T. Cole, B. A. McCutcheon and J. Ratliff, *Clin. Spine Surg.*, 2017, **30**, E1376–e1381.
- R. A. Deyo, B. I. Martin, W. Kreuter, J. G. Jarvik, H. Angier and S. K. Mirza, *J. Bone Joint Surg. Am.*, 2011, **93**, 1979–1986.
- B. I. Martin, S. K. Mirza, B. A. Comstock, D. T. Gray, W. Kreuter and R. A. Deyo, *Spine*, 2007, **32**, 382–387.
- A. D. Malter, B. McNeney, J. D. Loeser and R. A. Deyo, *Spine*, 1998, **23**, 814–820.
- M. Laubach, P. Kobbe and D. W. Huttmacher, *Biomaterials*, 2022, **288**, 121699.
- K. Kumar, *Spine*, 1996, **21**, 653–655.
- J. T. Hughes, *Paraplegia*, 1988, **26**, 71–82.
- S. Naderi, N. Andalkar and E. C. Benzel, *Neurosurgery*, 2007, **60**, 382–391.
- J. Lister, *Br. Med. J.*, 1867, **2**, 246–248.
- D. H. Robinson and A. H. Toledo, *J. Invest. Surg.*, 2012, **25**, 141–149.
- E. A. Underwood, *Proc. R. Soc. Med.*, 1945, **38**, 697–706.
- J. Dobson, *Ann. R. Coll. Surg. Engl.*, 1972, **50**, 54–65.
- T. M. Daniel, *Respir. Med.*, 2006, **100**, 1862–1870.
- S. L. de Kunder, K. Rijkers, I. J. M. H. Caelers, R. A. de Bie, P. J. Koehler and H. van Santbrink, *Spine*, 2018, **43**, 1161–1168.
- R. A. Deyo, A. Nachemson and S. K. Mirza, *N. Engl. J. Med.*, 2004, **350**, 722–726.
- R. N. Stauffer and M. B. Coventry, *J. Bone Jt. Surg.*, 1972, **54**, 756–768.
- R. B. Cloward, *J. Neurosurg.*, 1953, **10**, 154.
- J. S. Silber, D. G. Anderson, S. D. Daffner, B. T. Brislin, J. M. Leland, A. S. Hilibrand, A. R. Vaccaro and T. J. Albert, *Spine*, 2003, **28**, 134–139.
- R. L. Macdonald, M. G. Fehlings, C. H. Tator, A. Lozano, J. R. Fleming, F. Gentili, M. Bernstein, M. C. Wallace and R. R. Tasker, *J. Neurosurg.*, 1997, **86**, 990.
- A. Rieger, C. Holz, T. Marx, L. Sanchin and M. Menzel, *Neurosurgery*, 2003, **52**, 449–453; discussion 453–444.
- K. U. Lewandrowski, A. C. Hecht, T. F. DeLaney, P. A. Chapman, F. J. Hornicek and F. X. Pedlow, *Spine*, 2004, **29**, 1150–1158; discussion 1159.
- K. H. Bridwell, L. G. Lenke, K. W. McEnery, C. Baldus and K. Blanke, *Spine*, 1995, **20**, 1410–1418.
- D. E. Couture and C. L. Branch Jr., *Neurosurg. Focus*, 2004, **16**, E8.
- C. R. Fischer, R. Cassilly, W. Cantor, E. Edusei, Q. Hammouri and T. Errico, *Eur. Spine J.*, 2013, **22**, 1423–1435.
- V. Campana, G. Milano, E. Pagano, M. Barba, C. Cicione, G. Salonna, W. Lattanzi and G. Logroscino, *J. Mater. Sci.: Mater. Med.*, 2014, **25**, 2445–2461.
- H. C. Pape, A. Evans and P. Kobbe, *J. Orthop. Trauma*, 2010, **24**, S36–S40.
- G. Grabowski and C. A. Cornett, *J. Am. Acad. Orthop. Surg.*, 2013, **21**, 51–60.
- K. G. Heiple, V. M. Goldberg, A. E. Powell, G. D. Bos and J. M. Zika, *Orthop. Clin. N. Am.*, 1987, **18**, 179–185.
- J. A. Goulet, L. E. Senunas, G. L. Desilva and M. L. Greenfield, *Clin. Orthop. Relat. Res.*, 1997, 76–81.
- D. H. Kim, R. Rhim, L. Li, J. Martha, B. H. Swaim, R. J. Banco, L. G. Jenis and S. G. Tromanhauser, *Spine J.*, 2009, **9**, 886–892.
- R. C. Sasso, J. I. Williams, N. Dimasi and P. R. Meyer, *J. Bone Joint Surg. Am.*, 1998, **80**, 631–635.
- S. Khan, F. P. Cammisa, H. Sandhu, A. Diwan, F. Girardi and J. Lane, *J. Am. Acad. Orthop. Surg.*, 2005, **13**, 77–86.
- P. Ganguly, J. J. El-Jawhari, P. V. Giannoudis, A. N. Burska, F. Ponchel and E. A. Jones, *Cell Transplant.*, 2017, **26**, 1520–1529.
- R. Gao, M. Street, M. L. Tay, K. E. Callon, D. Naot, A. Lock, J. T. Munro, J. Cornish, J. Ferguson and D. Musson, *Spine*, 2018, **43**, E193–E199.



- 38 F. Migliorini, F. Cuzzo, E. Torsiello, F. Spiezia, F. Oliva and N. Maffulli, *J. Clin. Med.*, 2021, **10**, 4347.
- 39 F. Oliva, F. Migliorini, F. Cuzzo, E. Torsiello, F. Hildebrand and N. Maffulli, *J. Orthop. Trauma.*, 2021, **22**, 50.
- 40 D. S. Chun, K. C. Baker and W. K. Hsu, *Neurosurg. Focus*, 2015, **39**, E10.
- 41 M. B. Kornblum, J. S. Fischgrund, H. N. Herkowitz, D. A. Abraham, D. L. Berkower and J. S. Ditkoff, *Spine*, 2004, **29**, 726–733; discussion 733–724.
- 42 G. W. Bagby, *Orthopedics*, 1988, **11**, 931–934.
- 43 S. D. Kuslich, C. L. Ulstrom, S. L. Griffith, J. W. Ahern and J. D. Dowdle, *Spine*, 1998, **23**, 1267–1278; discussion 1279.
- 44 H. S. Sandhu, J. M. Toth, A. D. Diwan, H. B. Seim 3rd, L. E. Kanim, J. M. Kabo and A. S. Turner, *Spine*, 2002, **27**, 567–575.
- 45 N. F. Chen, Z. A. Smith, E. Stiner, S. Armin, H. Sheikh and L. T. Khoo, *J. Neurosurg. Spine*, 2010, **12**, 40–46.
- 46 P. C. McAfee, *J. Bone Joint Surg. Am.*, 1999, **81**, 859–880.
- 47 M. Kanayama, B. W. Cunningham, C. J. Haggerty, K. Abumi, K. Kaneda and P. C. McAfee, *J. Neurosurg.*, 2000, **93**, 259–265.
- 48 M. van Dijk, T. H. Smit, S. Sugihara, E. H. Burger and P. I. Wuisman, *Spine*, 2002, **27**, 682–688.
- 49 C. C. Niu, J. C. Liao, W. J. Chen and L. H. Chen, *J. Spinal Disord. Tech.*, 2010, **23**, 310–316.
- 50 S. Seaman, P. Kerezoudis, M. Bydon, J. C. Torner and P. W. Hitchon, *J. Clin. Neurosci.*, 2017, **44**, 23–29.
- 51 D. V. Patel, J. S. Yoo, S. S. Karmarkar, E. H. Lamoutte and K. Singh, *J. Spine Surg.*, 2019, S19–S24.
- 52 W. K. Hsu, C. L. Goldstein, M. F. Shamji, S. K. Cho, P. M. Arnold, M. G. Fehlings and T. E. Mroz, *Neurosurgery*, 2017, **80**, S100–S107.
- 53 C. M. Han, E. J. Lee, H. E. Kim, Y. H. Koh, K. N. Kim, Y. Ha and S. U. Kuh, *Biomaterials*, 2010, **31**, 3465–3470.
- 54 B. C. Cheng, S. Koduri, C. A. Wing, N. Woolery, D. J. Cook and R. C. Spiro, *Med. Devices*, 2018, **11**, 391–402.
- 55 H. Sakaura, A. Ohnishi, A. Yamagishi and T. Ohwada, *Asian Spine J.*, 2019, **13**, 248–253.
- 56 H. Manabe, T. Sakai, M. Morimoto, F. Tezuka, K. Yamashita, Y. Takata and K. Sairyo, *J. Med. Invest.*, 2019, **66**, 119–122.
- 57 M. Rickert, C. Fleege, T. Tarhan, S. Schreiner, M. R. Makowski, M. Rauschmann and M. Arabmotlagh, *Bone Jt. J.*, 2017, **99-B**, 1366–1372.
- 58 T. Hasegawa, H. Ushirozako, E. Shigeto, T. Ohba, H. Oba, K. Mukaiyama, S. Shimizu, Y. Yamato, K. Ide, Y. Shibata, T. Ojima, J. Takahashi, H. Haro and Y. Matsuyama, *Spine*, 2020, **45**, E892–E902.
- 59 R. Olivares-Navarrete, R. A. Gittens, J. M. Schneider, S. L. Hyzy, D. A. Haithcock, P. F. Ullrich, Z. Schwartz and B. D. Boyan, *Spine J.*, 2012, **12**, 265–272.
- 60 R. Olivares-Navarrete, S. L. Hyzy, P. J. Slosar, J. M. Schneider, Z. Schwartz and B. D. Boyan, *Spine*, 2015, **40**, 399–404.
- 61 F. Kong, Z. Nie, Z. Liu, S. Hou and J. Ji, *J. Photochem. Photobiol., B*, 2018, **187**, 120–125.
- 62 R. Ermawan, H. Corrigan and N. Wiyono, *J. Orthop.*, 2024, **50**, 22–28.
- 63 X. Han, Y. Zhu, C. Cui and Y. Wu, *Spine*, 2009, **34**, E618–E625.
- 64 R. Soegaard, C. E. Bünger, T. Christiansen, K. Høy, S. P. Eiskjaer and F. B. Christensen, *Spine*, 2007, **32**, 2405–2414.
- 65 R. Roy-Camille, M. Roy-Camille and C. Demeulenaere, *Presse Med.*, 1970, **78**, 1447–1448.
- 66 M. B. Kabins and J. N. Weinstein, *Iowa Orthop. J.*, 1991, 127–136.
- 67 J. M. Cotler, J. V. Vernace and J. A. Michalski, *Orthop. Clin. N. Am.*, 1986, **17**, 87–103.
- 68 H. Wang, Y. Zhao, Z. Mo, J. Han, Y. Chen, H. Yu, Q. Wang, J. Liu, C. Li, Y. Zhou and L. Xiang, *Clinics*, 2017, **72**, 609–617.
- 69 W. Yao, T. Zhou, K. Huang, M. Dai, F. Mo, J. Xu, Z. Cao, Q. Lai, B. Xie, R. Guo and B. Zhang, *Ann. Transl. Med.*, 2021, **9**, 669.
- 70 W. Qin, K. Chen, H. Chen, P. Yang, H. Yang and H. Mao, *World Neurosurg.*, 2020, **138**, e10–e16.
- 71 J. Li, L.-C. Zhang, J. Li, H. Zhang, J.-X. Zhao and W. Zhang, *BioMed Res. Int.*, 2020, **2020**, 5497030.
- 72 E. P. de Kater, A. Sakes, E. Edström, A. Elmi-Terander, G. Kraan and P. Breedveld, *Eur./ Spine J.*, 2022, **31**, 1553–1565.
- 73 M.-K. Hsieh, Y.-D. Li, Y.-J. Hsu, T.-T. Tsai, P.-L. Lai, D.-M. Lee and C.-L. Tai, *Appl. Sci.*, 2022, **12**, 6172.
- 74 C.-L. Tai, T.-T. Tsai, P.-L. Lai, Y.-L. Chen, M.-Y. Liu and L.-H. Chen, *PLoS One*, 2015, **10**, e0146294.
- 75 M. Law, A. F. Tencer and P. A. Anderson, *Spine*, 1993, **18**, 2438–2443.
- 76 R. Skinner, J. Maybee, E. Transfeldt, R. Venter and W. Chalmers, *Spine*, 1990, **15**, 195–201.
- 77 T. Hasegawa, A. Inufusa, Y. Imai, Y. Mikawa, T. H. Lim and H. S. An, *Spine J.*, 2005, **5**, 239–243.
- 78 B. Sandén, C. Olerud, C. Johansson and S. Larsson, *Spine*, 2001, **26**, 2673–2678.
- 79 S. Yi, D. C. Rim, S. W. Park, J. A. Murovic, J. Lim and J. Park, *World Neurosurg.*, 2015, **83**, 976–981.
- 80 L.-Y. Shi, A. Wang, F.-Z. Zang, J.-X. Wang, X.-W. Pan and H.-J. Chen, *Colloids Surf., B*, 2017, **160**, 22–32.
- 81 G. M. Liu, N. Kong, X. Y. Zhang, H. T. Bai, Y. Yao, H. Z. Han and Y. G. Luo, *Eur. J. Orthop. Surg. Traumatol.*, 2014, **24**(Suppl 1), S173–S182.
- 82 P. R. Harrington, *J. Bone Jt. Surg.*, 1962, **44**, 591–634.
- 83 A. Warburton, S. J. Girdler, C. M. Mikhail, A. Ahn and S. K. Cho, *Neurospine*, 2020, **17**, 101–110.
- 84 B. Meng, J. Bunch, D. Burton and J. Wang, *Eur. Spine J.*, 2021, **30**, 22–33.
- 85 J. Litak, M. Szymoniuk, W. Czyżewski, Z. Hoffman, J. Litak, L. Sakwa and P. Kamieniak, *Materials*, 2022, **15**, 3650.
- 86 H. Yoshihara, *Spine J.*, 2013, **13**, 1350–1358.
- 87 W. Li, H. Zhao, C. Li, T. Liu, J. Guan, Y. Yang and X. Yu, *J. Orthop. Surg. Res*, 2023, **18**, 348.
- 88 L. Qi, M. Li, S. Zhang, J. Xue and H. Si, *Acta Neurochir.*, 2013, **155**, 1187–1193.



- 89 R. K. Ponnappan, H. Serhan, B. Zarda, R. Patel, T. Albert and A. R. Vaccaro, *Spine J.*, 2009, **9**, 263–267.
- 90 C. Li, L. Liu, J. Y. Shi, K. Z. Yan, W. Z. Shen and Z. R. Yang, *Neurosurg. Rev.*, 2018, **41**, 375–389.
- 91 D. Grob, A. Benini, A. Junge and A. F. Mannion, *Spine*, 2005, **30**, 324–331.
- 92 X. Zhao, M. Niinomi, M. Nakai and J. Hieda, *Acta Biomater.*, 2012, **8**, 1990–1997.
- 93 H. Liu, M. Niinomi, M. Nakai, K. Cho, K. Narita, M. Şen, H. Shiku and T. Matsue, *Acta Biomater.*, 2015, **12**, 352–361.
- 94 F.-Y. Tsuang, Y.-Y. Hsieh, Y.-J. Kuo, C.-H. Chen, F.-H. Lin, C.-S. Chen and C.-J. Chiang, *PLoS One*, 2017, **12**, e0188034.
- 95 C. Lindsey, V. Deviren, Z. Xu, R. F. Yeh and C. M. Puttlitz, *Spine*, 2006, **31**, 1680–1687.
- 96 J. C. Dick and C. A. Bourgeault, *Spine*, 2001, **26**, 1668–1672.
- 97 K. Yamada, H. Sudo, N. Iwasaki and A. Chiba, *Spine*, 2020, **45**, E312–E318.
- 98 C. R. Faulks, D. T. Biddau, N. R. Munday, D. P. McKenzie and G. M. Malham, *J. Spine Surg.*, 2023, **9**, 409–421.
- 99 S. M. Kurtz and T. Lanman, in *PEEK Biomaterials Handbook*, ed. S. M. Kurtz, William Andrew Publishing, 2nd edn, 2019, pp. 281–289. DOI: [10.1016/B978-0-12-812524-3.00016-8](https://doi.org/10.1016/B978-0-12-812524-3.00016-8).
- 100 I. Gotman, *J. Endourol.*, 1997, **11**, 383–389.
- 101 H. Serhan, D. Mhatre, P. Newton, P. Giorgio and P. Sturm, *Clin. Spine Surg.*, 2013, **26**, E70–E74.
- 102 A. Angelliaume, E. Ferrero, K. Mazda, M. Le Hanneur, F. Accabed, J. S. de Gauzy and B. Ilharreborde, *Eur. Spine J.*, 2017, **26**, 1732–1738.
- 103 F. U. Ahmad, C. Sidani, R. Fourzali and M. Y. Wang, *J. Neurosurg. Spine.*, 2013, **19**, 629.
- 104 S. Rhalmi, S. Charette, M. Assad, C. Coillard and C. H. Rivard, *Eur. Spine J.*, 2007, **16**, 1063–1072.
- 105 Y. S. Kim, H. Y. Zhang, B. J. Moon, K. W. Park, K. Y. Ji, W. C. Lee, K. S. Oh, G. U. Ryu and D. H. Kim, *Neurosurg. Focus*, 2007, **22**, E10.
- 106 A. Biesiekierski, J. Wang, M. Abdel-Hady Gepreel and C. Wen, *Acta Biomater.*, 2012, **8**, 1661–1669.
- 107 A. Kirisits and W. K. Redekop, *Appl. Health Econ. Health policy*, 2013, **11**, 15–26.
- 108 A. J. Talia, M. L. Wong, H. C. Lau and A. H. Kaye, *J. Clin. Neurosci.*, 2015, **22**, 243–251.
- 109 M.-J. Reisener, M. Pumberger, J. Shue, F. P. Girardi and A. P. Hughes, *J. Spine Surg.*, 2020, **6**, 752–761.
- 110 R. J. Mobbs, K. Phan, G. Malham, K. Seex and P. J. Rao, *J. Spine Surg.*, 2015, **1**, 2–18.
- 111 M. A. Flierl, K. M. Beauchamp, G. E. Bolles, E. E. Moore and P. F. Stahel, *Patient Saf. Surg.*, 2009, **3**, 4.
- 112 P. Korovessis, G. Petsinis, G. Koureas, P. Iliopoulos and S. Zacharatos, *Spine*, 2006, **31**, 1014–1019.
- 113 Y. Robinson, S. K. Tschoeke, T. Finke, R. Kayser, W. Ertel and C. E. Heyde, *Acta Orthop.*, 2008, **79**, 660–664.
- 114 Y. Robinson, S. K. Tschoeke, R. Kayser, H. Boehm and C. E. Heyde, *Int. Orthop.*, 2009, **33**, 745–749.
- 115 M. Ruf, D. Stoltze, H. R. Merk, M. Ames and J. Harms, *Spine*, 2007, **32**, E275–E280.
- 116 M. Long and H. Rack, *Biomaterials*, 1998, **19**, 1621–1639.
- 117 T. Lanman and T. Hopkins, *Neurosurg. Focus*, 2004, **16**(3), E6.
- 118 C. R. Lippman, M. Hajjar, B. Abshire, G. Martin, R. W. Engelman and D. W. Cahill, *Neurosurg. Focus*, 2004, **16**, E4.
- 119 L. Marchi, N. Abdala, L. Oliveira, R. Amaral, E. Coutinho and L. Pimenta, *J. Neurosurg. Spine*, 2013, **19**, 110–118.
- 120 R. F. Frisch, I. Y. Luna, D. M. Brooks, G. Joshua and J. R. O'Brien, *J. Spine Surg.*, 2018, **4**, 62–71.
- 121 A. J. Kwon, W. D. Hunter, M. Moldavsky, K. Salloum and B. Bucklen, *J. Neurosurg. Spine*, 2016, **24**, 727–733.
- 122 Y. Hou and Z. Luo, *Spine*, 2009, **34**, E427–E433.
- 123 L. S. Chatham, V. V. Patel, C. M. Yakacki and R. Dana Carpenter, *J. Biomech. Eng.*, 2017, **139**, 0510051–0510058.
- 124 S. M. Kurtz and J. N. Devine, *Biomaterials*, 2007, **28**, 4845–4869.
- 125 J. M. Toth, M. Wang, B. T. Estes, J. L. Scifert, H. B. Seim and A. S. Turner, *Biomaterials*, 2006, **27**, 324–334.
- 126 J. M. Sadowska, K. J. Genoud, D. J. Kelly and F. J. O'Brien, *Mater. Today*, 2021, **46**, 136–154.
- 127 S. Weiner, W. Traub and H. D. Wagner, *J. Struct. Biol.*, 1999, **126**, 241–255.
- 128 S. Gómez, M. D. Vlad, J. López and E. Fernández, *Acta Biomater.*, 2016, **42**, 341–350.
- 129 M. Fantini and M. Curto, *Int. J. Interact. Des. Manuf.*, 2018, **12**, 585–596.
- 130 P. J. Rao, M. H. Pelletier, W. R. Walsh and R. J. Mobbs, *Orthop. Surg.*, 2014, **6**, 81–89.
- 131 R. D. Guyer, J. J. Abitbol, D. D. Ohnmeiss and C. Yao, *Spine*, 2016, **41**, E1146–E1150.
- 132 G. R. Cizek and L. M. Boyd, *Spine*, 2000, **25**, 2633–2636.
- 133 D. D. Robertson, G. B. Sharma, L. G. Gilbertson and J. D. Kang, *Spine*, 2009, **34**, 2792–2796.
- 134 M. H. Pelletier, N. Cordaro, V. M. Punjabi, M. Waites, A. Lau and W. R. Walsh, *Clin. Spine Surg.*, 2016, **29**, E208–E214.
- 135 O. Nemoto, T. Asazuma, Y. Yato, H. Imabayashi, H. Yasuoka and A. Fujikawa, *Eur. Spine J.*, 2014, **23**, 2150–2155.
- 136 H. Nakase, Y.-S. Park, H. Kimura, T. Sakaki and T. Morimoto, *Clin. Spine Surg.*, 2006, **19**, 353–357.
- 137 J. A. Disegi, *Injury*, 2000, **31**, D14–D17.
- 138 H. Kienapfel, C. Sprey, A. Wilke and P. Griss, *J. Arthroplasty*, 1999, **14**, 355–368.
- 139 R. A. Gittens, R. Olivares-Navarrete, Z. Schwartz and B. D. Boyan, *Acta Biomater.*, 2014, **10**, 3363–3371.
- 140 J. Hao, Y. Li, B. Li, X. Wang, H. Li, S. Liu, C. Liang and H. Wang, *Appl. Biochem. Biotechnol.*, 2017, **183**, 280–292.
- 141 D. N. Heo, W. K. Ko, H. R. Lee, S. J. Lee, D. Lee, S. H. Um, J. H. Lee, Y. H. Woo, L. G. Zhang, D. W. Lee and I. K. Kwon, *J. Colloid Interface Sci.*, 2016, **469**, 129–137.
- 142 P. J. Hou, K. L. Ou, C. C. Wang, C. F. Huang, M. Ruslin, E. Sugiatno, T. S. Yang and H. H. Chou, *J. Mech. Behav. Biomed. Mater.*, 2018, **79**, 173–180.



- 143 B. C. Bunker, P. C. Rieke, B. J. Tarasevich, A. A. Campbell, G. E. Fryxell, G. L. Graff, L. Song, J. Liu, J. W. Virden and G. L. McVay, *Science*, 1994, **264**, 48–55.
- 144 S. Mann, D. D. Archibald, J. M. Didymus, T. Douglas, B. R. Heywood, F. C. Meldrum and N. J. Reeves, *Science*, 1993, **261**, 1286–1292.
- 145 W. L. Murphy and D. J. Mooney, *J. Am. Chem. Soc.*, 2002, **124**, 1910–1917.
- 146 H. Ohgushi and A. I. Caplan, *J. Biomed. Mater. Res.*, 1999, **48**, 913–927.
- 147 H. Seeherman, J. Wozney and R. Li, *Spine*, 2002, **27**, S16–S23.
- 148 L. L. Hench, *J. Am. Ceram. Soc.*, 1991, **74**, 1487–1510.
- 149 W. L. Murphy, C. A. Simmons, D. Kaigler and D. J. Mooney, *J. Dent. Res.*, 2004, **83**, 204–210.
- 150 S. Szmukler-Moncler, D. Perrin, V. Ahossi, G. Magnin and J. P. Bernard, *J. Biomed. Mater. Res., Part B*, 2004, **68**, 149–159.
- 151 R. Olivares-Navarrete, S. L. Hyzy, R. A. s. Gittens, J. M. Schneider, D. A. Haithcock, P. F. Ullrich, P. J. Slosar, Z. Schwartz and B. D. Boyan, *Spine J.*, 2013, **13**, 1563–1570.
- 152 R. A. Gittens, R. Olivares-Navarrete, S. L. Hyzy, K. H. Sandhage, Z. Schwartz and B. D. Boyan, *Connect Tissue Res.*, 2014, **55**(Suppl 1), 164–168.
- 153 A. A. Zadpoor, *Biomater. Sci.*, 2015, **3**, 231–245.
- 154 A. A. Zadpoor, *Acta Biomater.*, 2019, **85**, 41–59.
- 155 S. J. P. Callens, R. J. C. Uyttendaele, L. E. Fratila-Apachitei and A. A. Zadpoor, *Biomaterials*, 2020, **232**, 119739.
- 156 S. Fujibayashi, M. Takemoto, M. Neo, T. Matsushita, T. Kokubo, K. Doi, T. Ito, A. Shimizu and T. Nakamura, *Eur. Spine J.*, 2011, **20**, 1486–1495.
- 157 M. Takemoto, S. Fujibayashi, M. Neo, K. So, N. Akiyama, T. Matsushita, T. Kokubo and T. Nakamura, *J. Neurosurg. Spine*, 2007, **7**, 435–443.
- 158 L. M. Bjursten, L. Rasmusson, S. Oh, G. C. Smith, K. S. Brammer and S. Jin, *J. Biomed. Mater. Res., Part A*, 2010, **92**, 1218–1224.
- 159 L. Pazos, P. Corengia and H. Svoboda, *J. Mech. Behav. Biomed. Mater.*, 2010, **3**, 416–424.
- 160 S. Yue, R. M. Pilliar and G. C. Weatherly, *J. Biomed. Mater. Res.*, 1984, **18**, 1043–1058.
- 161 J. Mouhyi, D. M. Dohan Ehrenfest and T. Albrektsson, *Clin. Implant Dent. Relat. Res.*, 2012, **14**, 170–183.
- 162 H. Chouirfa, H. Bouloussa, V. Migonney and C. Falentin-Daudré, *Acta Biomater.*, 2019, **83**, 37–54.
- 163 G. Schmidmaier, M. Kerstan, P. Schwabe, N. Südkamp and M. Raschke, *Injury*, 2017, **48**, 2235–2241.
- 164 K. Borcharding, D. Marx, L. Gätjen, N. Bormann, B. Wildemann, U. Specht, D. Salz, K. Thiel and I. Grunwald, *Materials*, 2019, **12**, 3838.
- 165 X. P. Tan, Y. J. Tan, C. S. L. Chow, S. B. Tor and W. Y. Yeong, *Mater. Sci. Eng., C*, 2017, **76**, 1328–1343.
- 166 X. Wang, S. Xu, S. Zhou, W. Xu, M. Leary, P. Choong, M. Qian, M. Brandt and Y. M. Xie, *Biomaterials*, 2016, **83**, 127–141.
- 167 C. Donaldson, T. Santro, M. Awad and A. Morokoff, *J. Spine Surg.*, 2024, **10**, 22–29.
- 168 Z. Zhang, H. Li, G. R. Fogel, D. Xiang, Z. Liao and W. Liu, *Comput. Biol. Med.*, 2018, **95**, 167–174.
- 169 Z. Zhang, H. Li, G. R. Fogel, Z. Liao, Y. Li and W. Liu, *World Neurosurg.*, 2018, **111**, e581–e591.
- 170 K. C. McGilvray, J. Easley, H. B. Seim, D. Regan, S. H. Berven, W. K. Hsu, T. E. Mroz and C. M. Puttlitz, *Spine J.*, 2018, **18**, 1250–1260.
- 171 P. Li, W. Jiang, J. Yan, K. Hu, Z. Han, B. Wang, Y. Zhao, G. Cui, Z. Wang, K. Mao, Y. Wang and F. Cui, *J. Biomed. Mater. Res., Part A*, 2019, **107**, 1386–1392.
- 172 S. H. Wu, Y. Li, Y. Q. Zhang, X. K. Li, C. F. Yuan, Y. L. Hao, Z. Y. Zhang and Z. Guo, *Artif. Organs*, 2013, **37**, E191–E201.
- 173 P. R. Krafft, B. Osburn, A. C. Vivas, G. Rao and P. Alikhani, *Spine Surg. Relat. Res.*, 2020, **4**, 171–177.
- 174 T. Makino, S. Takenaka, Y. Sakai, H. Yoshikawa and T. Kaito, *Global Spine J.*, 2020, 2192568220972334, DOI: [10.1177/2192568220972334](https://doi.org/10.1177/2192568220972334).
- 175 G. M. Malham, R. M. Parker, B. Goss, C. M. Blecher and Z. E. Ballok, *Spine*, 2014, **39**, E1303–E1310.
- 176 T. V. Le, A. A. Baaj, E. Dakwar, C. J. Burkett, G. Murray, D. A. Smith and J. S. Uribe, *Spine*, 2012, **37**, 1268–1273.
- 177 P. A. Gunatillake and R. Adhikari, *Biosynthetic Polymers for Medical Applications*, 2016, pp. 33–62.
- 178 S. Vadapalli, K. Sairyo, V. K. Goel, M. Robon, A. Biyani, A. Khandha and N. A. Ebraheim, *Spine*, 2006, **31**, E992–E998.
- 179 J. R. Parsons, S. Bhayani, H. Alexander and A. B. Weiss, *Clin. Orthop. Relat. Res.*, 1985, **196**, 69–76.
- 180 F. C. Ewald, C. B. Sledge, J. M. Corson, R. M. Rose and E. L. Radin, *Clin. Orthop. Relat. Res.*, 1976, **115**, 213–219.
- 181 H. E. Groth and J. M. Shilling, *J. Orthop. Res.*, 1983, **1**, 129–135.
- 182 J. M. Toth, in *PEEK Biomaterials Handbook*, ed. S. M. Kurtz, William Andrew Publishing, Oxford, 2012, pp. 81–92. DOI: [10.1016/B978-1-4377-4463-7.10007-7](https://doi.org/10.1016/B978-1-4377-4463-7.10007-7).
- 183 L. M. Wenz, K. Merritt, S. A. Brown, A. Moet and A. D. Steffee, *J. Biomed. Mater. Res.*, 1990, **24**, 207–215.
- 184 D. F. Williams, A. McNamara and R. M. Turner, *J. Mater. Sci. Lett.*, 1987, **6**, 188–190.
- 185 O. Petillo, G. Peluso, L. Ambrosio, L. Nicolais, W. J. Kao and J. M. Anderson, *J. Biomed. Mater. Res.*, 1994, **28**, 635–646.
- 186 J. M. Toth, M. Wang, B. T. Estes, J. L. Scifert, H. B. Seim 3rd and A. S. Turner, *Biomaterials*, 2006, **27**, 324–334.
- 187 B. J. Yoon, F. Xavier, B. R. Walker, S. Grinberg, F. P. Cammisa and C. Abjornson, *Spine J.*, 2016, **16**, 1238–1243.
- 188 M. C. Kuo, C. M. Tsai, J. C. Huang and M. Chen, *Mater. Chem. Phys.*, 2005, **90**, 185–195.
- 189 J. W. Duncan and R. A. Bailey, *Eur. Spine J.*, 2013, **22**, 439–445.
- 190 Y. Kim, *Spine*, 2001, **26**, 1437–1442.
- 191 R. F. Kersten, S. M. van Gaalen, A. de Gast and F. C. Öner, *Spine J.*, 2015, **15**, 1446–1460.



- 192 S. Tanida, S. Fujibayashi, B. Otsuki, K. Masamoto, Y. Takahashi, T. Nakayama and S. Matsuda, *Spine*, 2016, **41**, E1216–e1222.
- 193 Y. Assem, R. J. Mobbs, M. H. Pelletier, K. Phan and W. R. Walsh, *Eur. Spine J.*, 2017, **26**, 593–605.
- 194 S. Jain, A. E. M. Eltorai, R. Ruttiman and A. H. Daniels, *Orthop. Surg.*, 2016, **8**, 278–284.
- 195 W. R. Walsh, N. Bertollo, C. Christou, D. Schaffner and R. J. Mobbs, *Spine J.*, 2015, **15**, 1041–1049.
- 196 C. M. F. Meers, G. B. M. Verleye, D. Smeets, H. Y. R. Van Hauwermeiren, D. Loeckx, K. Willems, V. G. M. G. B. Siau and P. J. M. E. Lauweryns, *Int. J. Spine Surg.*, 2015, **9**, 35.
- 197 N. Aebli, J. Krebs, H. Stich, P. Schawalder, M. Walton, D. Schwenke, H. Gruner, B. Gasser and J. C. Theis, *J. Biomed. Mater. Res., Part A*, 2003, **66**, 356–363.
- 198 A. Wieling, *Eur. Cells Mater.*, 2009, **17**, 10.
- 199 D. M. Devine, J. Hahn, R. G. Richards, H. Gruner, R. Wieling and S. G. Pearce, *J. Biomed. Mater. Res., Part B*, 2013, **101**, 591–598.
- 200 A. Kienle, N. Graf and H. J. Wilke, *Spine J.*, 2016, **16**, 235–242.
- 201 B. W. Cunningham, C. M. Orbegoso, A. E. Dmitriev, N. J. Hallab, J. C. Seftor, P. Asdourian and P. C. McAfee, *Spine J.*, 2003, **3**, 19–32.
- 202 B. W. Cunningham, C. M. Orbegoso, A. E. Dmitriev, N. J. Hallab, J. C. Seftor and P. C. McAfee, *Spine*, 2002, **27**, 1971–1981.
- 203 H.-D. Kim, K.-S. Kim, S.-C. Ki and Y.-S. Choi, *Asian Spine J.*, 2007, **1**, 1–7.
- 204 K. J. Schnake, N. Fleiter, C. Hoffmann, A. Pingel, M. Scholz, A. Langheinrich and F. Kandziora, *Eur. Spine J.*, 2021, **30**, 114–121.
- 205 K. Borcherdig, G. Schmidmaier, G. O. Hofmann and B. Wildemann, *Injury*, 2020, **52**, S106–S111.
- 206 C. Yao, D. Storey and T. J. Webster, *Int. J. Nanomed.*, 2007, **2**, 487–492.
- 207 S. W. Ha, M. Kirch, F. Birchler, K. L. Eckert, J. Mayer, E. Wintermantel, C. Sittig, I. Pfund-Klingenfuss, M. Textor, N. D. Spencer, M. Guecheva and H. Vonmont, *J. Mater. Sci. Mater. Med.*, 1997, **8**, 683–690.
- 208 A. Barik and N. Chakravorty, *Trends Biosci. Res.*, 2020, 1–17.
- 209 M. Goldberg, R. Langer and X. Jia, *J. Biomater. Sci., Polym. Ed.*, 2007, **18**, 241–268.
- 210 M. Qu, X. Jiang, X. Zhou, C. Wang, Q. Wu, L. Ren, J. Zhu, S. Zhu, P. Tebon, W. Sun and A. Khademhosseini, *Adv. Healthcare Mater.*, 2020, **9**, 1901714.
- 211 A. Dehghanhadikolaei and B. Fotovvati, *Materials*, 2019, **12**, 1795.
- 212 J. H. Lee, H. L. Jang, K. M. Lee, H. R. Baek, K. Jin, K. S. Hong, J. H. Noh and H. K. Lee, *Acta Biomater.*, 2013, **9**, 6177–6187.
- 213 J. W. Durham III, M. J. Allen and A. Rabiei, *J. Biomed. Mater. Res., Part B*, 2017, **105**, 560–567.
- 214 S. Yu, K. P. Hariram, R. Kumar, P. Cheang and K. K. Aik, *Biomaterials*, 2005, **26**, 2343–2352.
- 215 S. Barkarmo, M. Andersson, F. Currie, P. Kjellin, R. Jimbo, C. B. Johansson and V. Stenport, *J. Biomater. Appl.*, 2014, **29**, 737–747.
- 216 P. Johansson, R. Jimbo, Y. Naito, P. Kjellin, F. Currie and A. Wennerberg, *Int. J. Nanomed.*, 2016, **11**, 1435–1442.
- 217 S. Stübinger, A. Drechsler, A. Bürki, K. Klein, P. Kronen and B. von Rechenberg, *J. Biomed. Mater. Res., Part B*, 2016, **104**, 1182–1191.
- 218 M. Røkkum, A. Reigstad, C. B. Johansson and T. Albrektsson, *J. Bone Jt. Surg. Br.*, 2003, **85**, 440–447.
- 219 T. Shimizu, S. Fujibayashi, S. Yamaguchi, K. Yamamoto, B. Otsuki, M. Takemoto, M. Tsukanaka, T. Kizuki, T. Matsushita, T. Kokubo and S. Matsuda, *Acta Biomater.*, 2016, **35**, 305–317.
- 220 T. Kizuki, T. Matsushita and T. Kokubo, *J. Mater. Sci.: Mater. Med.*, 2015, **26**, 41.
- 221 M. E. Pätzi, J. A. Hautaniemi, H. M. Rahiala, T. O. Peltola and I. M. O. Kangasniemi, *J. Sol-Gel Sci. Technol.*, 1998, **11**, 55–66.
- 222 T. Shimizu, S. Fujibayashi, S. Yamaguchi, B. Otsuki, Y. Okuzu, T. Matsushita, T. Kokubo and S. Matsuda, *PLoS One*, 2017, **12**, e0184495.
- 223 J. Khoury, S. R. Kirkpatrick, M. Maxwell, R. E. Cherian, A. Kirkpatrick and R. C. Svrluga, *Nucl. Instrum. Methods Phys. Res., Sect. B*, 2013, **307**, 630–634.
- 224 K. L. Wong, C. T. Wong, W. C. Liu, H. B. Pan, M. K. Fong, W. M. Lam, W. L. Cheung, W. M. Tang, K. Y. Chiu, K. D. Luk and W. W. Lu, *Biomaterials*, 2009, **30**, 3810–3817.
- 225 X. Wu, X. Liu, J. Wei, J. Ma, F. Deng and S. Wei, *Int. J. Nanomed.*, 2012, **7**, 1215–1225.
- 226 R. Wauthle, J. van der Stok, S. Amin Yavari, J. Van Humbeeck, J.-P. Kruth, A. A. Zadpoor, H. Weinans, M. Mulier and J. Schrooten, *Acta Biomater.*, 2015, **14**, 217–225.
- 227 K. B. Sagomonyants, M. Hakim-Zargar, A. Jhaveri, M. S. Aronow and G. Gronowicz, *J. Orthop. Res.*, 2011, **29**, 609–616.
- 228 M. Hanc, S. K. Fokter, M. Vogrin, A. Molicnik and G. Recnik, *Eur. J. Orthop. Surg. Traumatol.*, 2016, **26**, 1–7.
- 229 J. D. Boby, G. J. Stackpool, S. A. Hacking, M. Tanzer and J. J. Krygier, *J. Bone Jt. Surg. Br.*, 1999, **81**, 907–914.
- 230 M. Lu, S. Xu, Z.-X. Lei, D. Lu, W. Cao, M. Huttula, C.-H. Hou, S.-H. Du, W. Chen, S.-W. Dai, H.-M. Li and D.-D. Jin, *China Med. J.*, 2019, **132**, 51–62.
- 231 S. K. Sinclair, G. J. Konz, J. M. Dawson, R. T. Epperson and R. D. Bloebaum, *Spine*, 2012, **37**, E571–E580.
- 232 X. Zou, H. Li, M. Bünger, N. Egund, M. Lind and C. Bünger, *Spine J.*, 2004, **4**, 99–105.
- 233 J. Matejka, J. Zeman and J. Belatka, *Acta Chir. Orthop. Traumatol. Cech.*, 2009, **76**, 388–393.
- 234 M. B. Lequin, D. Verbaan and G. J. Bouma, *J. Neurosurg. Spine*, 2014, **20**, 617–622.
- 235 C. A. Elliott, R. Fox, R. Ashforth, S. Gourishankar and A. Nataraj, *J. Neurosurg. Spine*, 2016, **24**, 496–501.
- 236 R. F. Kersten, S. M. van Gaalen, M. P. Arts, K. C. Roes, A. de Gast, T. P. Corbin and F. C. Öner, *BMC Musculoskelet. Disord.*, 2014, **15**, 57.



- 237 T. J. Webster, A. A. Patel, M. N. Rahaman and B. Sonny Bal, *Acta Biomater.*, 2012, **8**, 4447–4454.
- 238 M. P. Arts, J. F. C. Wolfs and T. P. Corbin, *BMC Musculoskelet. Disord.*, 2013, **14**, 244.
- 239 D. J. Gorth, S. Puckett, B. Ercan, T. J. Webster, M. Rahaman and B. S. Bal, *Int. J. Nanomed.*, 2012, **7**, 4829–4840.
- 240 R. F. M. R. Kersten, F. C. Öner, M. P. Arts, M. Mitroiu, K. C. B. Roes, A. de Gast and S. M. van Gaalen, *Glob. Spine J.*, 2022, **12**, 1687–1695.
- 241 M. P. Arts, J. F. C. Wolfs and T. P. Corbin, *Eur. Spine J.*, 2017, **26**, 2372–2379.
- 242 G. C. Calvert, G. VanBuren Huffmon 3rd, W. M. Rambo Jr., M. W. Smith, B. J. McEntire and B. S. Bal, *J. Spine Surg.*, 2020, **6**, 33–48.
- 243 W. J. Buehler, J. V. Gilfrich and R. Wiley, *J. Appl. Phys.*, 1963, **34**, 1475–1477.
- 244 Y. Yasenchuk, E. Marchenko, V. Gunther, A. Radkevich, O. Kokorev, S. Gunther, G. Baigonakova, V. Hodorenko, T. Chekalkin, J.-h. Kang, S. Weiss and A. Obrosof, *Materials*, 2019, **12**, 2405.
- 245 A. Wadood, *Adv. Mater. Sci. Eng.*, 2016, **2016**, 4173138.
- 246 K. Otsuka and C. M. Wayman, *Shape memory materials*, Cambridge university press, 1999.
- 247 A. Saigal and M. Fonte, *Mater. Sci. Eng., A*, 2011, **528**, 5536–5550.
- 248 M. Niinomi, *Sci. Technol. Adv. Mater.*, 2003, **4**, 445–454.
- 249 V. Brailovski, S. Prokoshkin, M. Gauthier, K. Inaekyan, S. Dubinskiy, M. Petrzhik and M. Filonov, *Mater. Sci. Eng., C*, 2011, **31**, 643–657.
- 250 A. Hensten-Pettersen, *Eur. J. Oral Sci.*, 1998, **106**, 707–712.
- 251 S. Shabalovskaya and J. Van Humbeeck, in *Shape Memory Alloys for Biomedical Applications*, ed. T. Yoneyama and S. Miyazaki, Woodhead Publishing, 2009, pp. 194–233. DOI: [10.1533/9781845695248.1.194](https://doi.org/10.1533/9781845695248.1.194).
- 252 J. Schrooten, M. Assad, J. V. Humbeeck and M. A. Leroux, *Smart Mater. Struct.*, 2007, **16**, S145–S154.
- 253 M. Assad, P. Jarzem, M. A. Leroux, C. Coillard, A. V. Chernyshov, S. Charette and C. H. Rivard, *J. Biomed. Mater. Res., Part B*, 2003, **64**, 107–120.
- 254 F. H. Abduljabbar, A. M. Makhdom, M. Rajeh, A. R. Tales, J. Mathew, J. Ouellet, M. Weber and P. Jarzem, *Glob. Spine J.*, 2017, **7**, 780–786.
- 255 V. Letchuman, L. Ampie, W. Choy, J. D. DiDomenico, H. R. Syed and A. L. Buchholz, *Neurosurg. Focus*, 2021, **50**, E8.
- 256 Z. Buser, D. S. Brodke, J. A. Youssef, H.-J. Meisel, S. L. Myhre, R. Hashimoto, J.-B. Park, S. T. Yoon and J. C. Wang, *J. Neurosurg. Spine*, 2016, **25**, 509–516.
- 257 E. D. Arrington, W. J. Smith, H. G. Chambers, A. L. Bucknell and N. A. Davino, *Clin. Orthop. Relat. Res.*, 1996, 300–309, DOI: [10.1097/00003086-199608000-00037](https://doi.org/10.1097/00003086-199608000-00037).
- 258 R. Dimitriou, G. I. Mataliotakis, A. G. Angoules, N. K. Kanakaris and P. V. Giannoudis, *Injury*, 2011, **42**(Suppl 2), S3–15.
- 259 J. S. Silber, D. G. Anderson, S. D. Daffner, B. T. Brislin, J. M. Leland, A. S. Hilibrand, A. R. Vaccaro and T. J. Albert, *Spine*, 2003, **28**, 134–139.
- 260 P. A. Robertson and A. C. Wray, *Spine*, 2001, **26**, 1473–1476.
- 261 A. Kannan, S. N. Dodwad and W. K. Hsu, *J. Spinal Disord. Tech*, 2015, **28**, 163–170.
- 262 M. K. Aghi, B. P. Walcott, B. V. Nahed, G. L. Cvetanovich, K. T. Kahle, N. Redjal and J. V. Coumans, *J. Clin. Neurosci.*, 2011, **18**, 1193–1196.
- 263 K. Y. Ha, J. S. Lee and K. W. Kim, *Spine*, 2009, **34**, 1663–1668.
- 264 K. W. Kim, K. Y. Ha, M. S. Moon, Y. S. Kim, S. Y. Kwon and Y. K. Woo, *Spine*, 1999, **24**, 428–433.
- 265 D. Delawi, M. C. Kruyt, Y. Huipin, K. L. Vincken, J. D. de Bruijn, F. C. Oner and W. J. Dhert, *Tissue Eng., Part C*, 2013, **19**, 821–828.
- 266 M. Street, R. Gao, W. Martis, J. Munro, D. Musson, J. Cornish and J. Ferguson, *Spine Deform.*, 2017, **5**, 231–237.
- 267 E. M. Fragkakis, J. J. El-Jawhari, R. A. Dunsmuir, P. A. Millner, A. S. Rao, K. T. Henshaw, I. Pountos, E. Jones and P. V. Giannoudis, *PLoS One*, 2018, **13**, e0197969.
- 268 K.-W. Wong, H.-W. Wang, C.-S. Chien, C.-H. Li, C.-B. Li and C.-L. Lin, *Expert Rev. Med. Devices*, 2024, 1–8, DOI: [10.1080/17434440.2024.2367688](https://doi.org/10.1080/17434440.2024.2367688).
- 269 R. M. Duarte, P. Varanda, R. L. Reis, A. R. C. Duarte and J. Correia-Pinto, *Tissue Eng., Part B*, 2017, **23**, 540–551.
- 270 C.-C. Niu, S.-S. Lin, W.-J. Chen, S.-J. Liu, L.-H. Chen, C.-Y. Yang, C.-J. Wang, L.-J. Yuan, P.-H. Chen and H.-Y. Cheng, *J. Orthop. Surg. Res.*, 2015, **10**, 111.
- 271 Y. Gu, L. Chen, H.-Y. Niu, X.-F. Shen and H.-L. Yang, *J. Biomater. Appl.*, 2016, **30**, 1251–1260.
- 272 A. Tuchman, D. S. Brodke, J. A. Youssef, H.-J. Meisel, J. R. Dettori, J.-B. Park, S. T. Yoon and J. C. Wang, *Glob. Spine J.*, 2016, **6**, 592–606.
- 273 W. K. Hsu, M. S. Nickoli, J. C. Wang, J. R. Lieberman, H. S. An, S. T. Yoon, J. A. Youssef, D. S. Brodke and C. M. McCullough, *Glob. Spine J.*, 2012, **2**, 239–248.
- 274 C. Delloye, O. Cornu, V. Druetz and O. Barbier, *J. Bone Joint. Surg. Br.*, 2007, **89-B**, 574–580.
- 275 V. Grover, A. Kapoor, R. Malhotra and S. Sachdeva, *Indian J. Dent. Res.*, 2011, **22**, 496.
- 276 A. S. Greenwald, S. D. Boden, V. M. Goldberg, Y. Khan, C. T. Laurencin and R. N. Rosier, *J. Bone Jt. Surg. Am.*, 2001, **83-A**(Suppl 2 Pt 2), 98–103.
- 277 T. Kurien, R. G. Pearson and B. E. Scammell, *Bone Joint J.*, 2013, **95-B**, 583–597.
- 278 W. G. De Long Jr., T. A. Einhorn, K. Koval, M. McKee, W. Smith, R. Sanders and T. Watson, *J. Bone Jt. Surg. Am.*, 2007, **89**, 649–658.
- 279 M. R. Urist, *Science*, 1965, **150**, 893–899.
- 280 B. Peterson, P. G. Whang, R. Iglesias, J. C. Wang and J. R. Lieberman, *J. Bone Jt. Surg.*, 2004, **86**, 2243–2250.



- 281 K. Tilkeridis, P. Touzopoulos, A. Ververidis, S. Christodoulou, K. Kazakos and G. I. Drosos, *World J. Orthop.*, 2014, **5**, 30–37.
- 282 P. V. Giannoudis, H. Dinopoulos and E. Tsiridis, *Injury*, 2005, **36**(Suppl 3), S20–S27.
- 283 M. C. Makhni, J. M. Caldwell, C. Saifi, C. R. Fischer, R. A. Lehman, L. G. Lenke and F. Y. Lee, *Regen. Med.*, 2016, **11**, 211–222.
- 284 F. Baumann, W. Krutsch, C. Pfeifer, C. Neumann, M. Nerlich and M. Loibl, *Acta Chir. Orthop. Traumatol. Cech.*, 2015, **82**, 119–125.
- 285 B. Aghdasi, S. R. Montgomery, M. D. Daubs and J. C. Wang, *Surgeon*, 2013, **11**, 39–48.
- 286 R. M. Ajiboye, J. T. Hamamoto, M. A. Eckardt and J. C. Wang, *Eur. Spine J.*, 2015, **24**, 2567–2572.
- 287 A. Gupta, N. Kukkar, K. Sharif, B. J. Main, C. E. Albers and S. F. El-Amin III, *World J. Orthop.*, 2015, **6**, 449.
- 288 C. E. Gillman and A. C. Jayasuriya, *Mater. Sci. Eng.*, *C*, 2021, **130**, 112466.
- 289 T. T. Roberts and A. J. Rosenbaum, *Organogenesis*, 2012, **8**, 114–124.
- 290 W. Wang and K. W. K. Yeung, *Bioact. Mater.*, 2017, **2**, 224–247.
- 291 H. C. Pape, A. Evans and P. Kobbe, *J. Orthop. Trauma*, 2010, **24**(Suppl 1), S36–S40.
- 292 H.-S. Sohn and J.-K. Oh, *Biomater. Res.*, 2019, **23**, 9.
- 293 J. M. Bouler, P. Pilet, O. Gauthier and E. Verron, *Acta Biomater.*, 2017, **53**, 1–12.
- 294 H. H. K. Xu, M. D. Weir, E. F. Burguera and A. M. Fraser, *Biomaterials*, 2006, **27**, 4279–4287.
- 295 E. U. Conrad, D. R. Gretch, K. R. Obermeyer, M. S. Moogk, M. Sayers, J. J. Wilson and D. M. Strong, *J. Bone Jt. Surg. Am.*, 1995, **77**, 214–224.
- 296 W. R. Moore, S. E. Graves and G. I. Bain, *ANZ J. Surg.*, 2001, **71**, 354–361.
- 297 A. W. James, G. LaChaud, J. Shen, G. Asatrian, V. Nguyen, X. Zhang, K. Ting and C. Soo, *Tissue Eng., Part B*, 2016, **22**, 284–297.
- 298 M. P. Bostrom and D. A. Seigerman, *HSS J.*, 2005, **1**, 9–18.
- 299 J. R. Jones, D. S. Brauer, L. Hupa and D. C. Greenspan, *Int. J. Appl. Glass Sci.*, 2016, **7**, 423–434.
- 300 R. Z. LeGeros, *Clin. Orthop. Relat. Res.*, 2002, 81–98, DOI: [10.1097/00003086-200202000-00009](https://doi.org/10.1097/00003086-200202000-00009).
- 301 G. Zimmermann and A. Moghaddam, *Injury*, 2011, **42**(Suppl 2), S16–S21.
- 302 R. M. Pilliar, M. J. Filiaggi, J. D. Wells, M. D. Grynepas and R. A. Kandel, *Biomaterials*, 2001, **22**, 963–972.
- 303 E. P. Frankenburg, S. A. Goldstein, T. W. Bauer, S. A. Harris and R. D. Poser, *J. Bone Jt. Surg. Am.*, 1998, **80**, 1112–1124.
- 304 M. Ikenaga, P. Hardouin, J. Lemaître, H. Andrianjatovo and B. Flautre, *J. Biomed. Mater. Res.*, 1998, **40**, 139–144.
- 305 M. A. Plantz, E. B. Gerlach and W. K. Hsu, *Int. J. Spine Surg.*, 2021, **15**, 104.
- 306 R. A. Kapur, R. Amirfeyz, V. Wylde, A. W. Blom, I. W. Nelson and J. Hutchinson, *Arch. Orthop. Trauma Surg.*, 2010, **130**, 641–647.
- 307 L. A. van Dijk, D. Barbieri, F. Barrère-de Groot, H. Yuan, R. Oliver, C. Christou, W. R. Walsh and J. D. de Bruijn, *J. Biomed. Mater. Res., Part B*, 2019, **107**, 2080–2090.
- 308 A. M. Lehr, F. C. Oner, D. Delawi, R. K. Stellato, E. A. Hoebink, D. H. R. Kempen, J. L. C. van Susante, R. M. Castelein and M. C. Kruyt, *Spine*, 2020, **45**, 944–951.
- 309 J. E. Inglis, A. M. Goodwin, S. N. Divi and W. K. Hsu, *Int. J. Spine Surg.*, 2023, **17**, S18.
- 310 A. M. Lehr, F. C. Oner, D. Delawi, R. K. Stellato, E. A. Hoebink, D. H. R. Kempen, J. L. C. van Susante, R. M. Castelein and M. C. Kruyt, *Spine*, 2020, **45**, 1403–1410.
- 311 L. A. van Dijk, R. Duan, X. Luo, D. Barbieri, M. Pelletier, C. Christou, A. J. W. P. Rosenberg, H. Yuan, F. Barrère-de Groot, W. R. Walsh and J. D. de Bruijn, *JOR Spine*, 2018, **1**, e1039.
- 312 B. H. Ziran, W. R. Smith and S. J. Morgan, *J. Trauma*, 2007, **63**, 1324–1328.
- 313 W. J. Chen, T. T. Tsai, L. H. Chen, C. C. Niu, P. L. Lai, T. S. Fu and K. McCarthy, *Spine*, 2005, **30**, 2293–2297.
- 314 L. Y. Dai and L. S. Jiang, *Spine*, 2008, **33**, 1299–1304.
- 315 A. E. Jakus, A. L. Rutz, S. W. Jordan, A. Kannan, S. M. Mitchell, C. Yun, K. D. Koube, S. C. Yoo, H. E. Whiteley, C.-P. Richter, R. D. Galiano, W. K. Hsu, S. R. Stock, E. L. Hsu and R. N. Shah, *Sci. Transl. Med.*, 2016, **8**, 358ra127–358ra127.
- 316 L. L. Hench, R. J. Splinter, W. C. Allen and T. K. Greenlee, *J. Biomed. Mater. Res.*, 1971, **5**, 117–141.
- 317 I. D. Xynos, M. V. Hukkanen, J. J. Batten, L. D. Buttery, L. L. Hench and J. M. Polak, *Calcif. Tissue Int.*, 2000, **67**, 321–329.
- 318 I. D. Xynos, A. J. Edgar, L. D. Buttery, L. L. Hench and J. M. Polak, *J. Biomed. Mater. Res.*, 2001, **55**, 151–157.
- 319 Z. Qiu, H. Yang, J. Wu, L. Wei and J. Li, *J. Int. Med. Res.*, 2009, **37**, 737–745.
- 320 Ö. H. Andersson and I. Kangasniemi, *J. Biomed. Mater. Res.*, 1991, **25**, 1019–1030.
- 321 M. R. Filgueiras, G. La Torre and L. L. Hench, *J. Biomed. Mater. Res.*, 1993, **27**, 445–453.
- 322 L. L. Hench, R. J. Splinter, W. C. Allen and T. K. Greenlee, *J. Biomed. Mater. Res., Part A*, 1971, **5**, 117–141.
- 323 C. Xu, P. Su, X. Chen, Y. Meng, W. Yu, A. P. Xiang and Y. Wang, *Biomaterials*, 2011, **32**, 1051–1058.
- 324 L. A. van Dijk, F. Barrère-de Groot, A. Rosenberg, M. Pelletier, C. Christou, J. D. de Bruijn and W. R. Walsh, *Clin. Spine Surg.*, 2020, **33**, E276–e287.
- 325 J. H. Lee, H. S. Ryu, J. H. Seo, D. Y. Lee, B. S. Chang and C. K. Lee, *Clin. Orthop. Surg.*, 2014, **6**, 87–95.
- 326 J. M. Schmitt, D. C. Buck, S.-P. Joh, S. E. Lynch and J. O. Hollinger, *J. Periodontol.*, 1997, **68**, 1043–1053.
- 327 A. Moreira-Gonzalez, C. Loboeki, K. Barakat, L. Andrus, M. Bradford, M. Gilsdorf and I. T. Jackson, *J. Craniofac. Surg.*, 2005, **16**, 63–70.
- 328 H. Kobayashi, A. S. Turner, H. B. Seim III, T. Kawamoto and T. W. Bauer, *J. Biomed. Mater. Res., Part A*, 2010, **92**, 596–603.



- 329 M. R. Urist and B. S. Strates, *J. Dent. Res.*, 1971, **50**, 1392–1406.
- 330 K. R. Garrison, I. Shemilt, S. Donell, J. J. Ryder, M. Mugford, I. Harvey, F. Song and V. Alt, *Cochrane Database Syst. Rev.*, 2010, **6**, CD006950.
- 331 G. E. Friedlaender, C. R. Perry, J. D. Cole, S. D. Cook, G. Cierny, G. F. Muschler, G. A. Zych, J. H. Calhoun, A. J. LaForte and S. Yin, *J. Bone Jt. Surg. Am.*, 2001, **83-A**(Suppl 1), S151–S158.
- 332 S. A. Gittens, K. Bagnall, J. R. Matyas, R. Löbenberg and H. Uludag, *J. Controlled Release*, 2004, **98**, 255–268.
- 333 J. P. Gorski, *Crit. Rev. Oral Biol. Med.*, 1998, **9**, 201–223.
- 334 J. P. Gorski, D. Griffin, G. Dudley, C. Stanford, R. Thomas, C. Huang, E. Lai, B. Karr and M. Solursh, *J. Biol. Chem.*, 1990, **265**, 14956–14963.
- 335 Y. Liu, E. B. Hunziker, P. Layrolle, J. D. De Bruijn and K. De Groot, *Tissue Eng.*, 2004, **10**, 101–108.
- 336 T. Matsumoto, M. Okazaki, M. Inoue, S. Yamaguchi, T. Kusunose, T. Toyonaga, Y. Hamada and J. Takahashi, *Biomaterials*, 2004, **25**, 3807–3812.
- 337 A. Sachse, A. Wagner, M. Keller, O. Wagner, W. D. Wetzel, F. Layher, R. A. Venbrocks, P. Hortschansky, M. Pietraszczyk, B. Wiederanders, H. J. Hempel, J. Bossert, J. Horn, K. Schmuck and J. Mollenhauer, *Bone*, 2005, **37**, 699–710.
- 338 S. Cecchi, S. J. Bennet and M. Arora, *J. Orthop. Translat.*, 2016, **4**, 28–34.
- 339 A. R. Vaccaro, P. G. Whang, T. Patel, F. M. Phillips, D. G. Anderson, T. J. Albert, A. S. Hilibrand, R. S. Brower, M. F. Kurd, A. Appannagari, M. Patel and J. S. Fischgrund, *Spine J.*, 2008, **8**, 457–465.
- 340 J. Munns, D. K. Park and K. Singh, *Orthop. Res. Rev.*, 2009, **1**, 11–21.
- 341 J. W. Hustedt and D. J. Blizzard, *Yale J. Biol. Med.*, 2014, **87**, 549–561.
- 342 J. Everding, J. Stolberg-Stolberg, M. J. Raschke and R. Stange, *Unfallchirurg*, 2019, **122**, 534–543.
- 343 E. R. Balmayor and M. van Griensven, *Front. Bioeng. Biotechnol.*, 2015, **3**, 9.
- 344 E. Tsiridis, N. Upadhyay and P. Giannoudis, *Injury*, 2007, **38**(Suppl 1), S11–S25.
- 345 K. D. Hankenson, K. Gagne and M. Shaughnessy, *Adv. Drug Delivery Rev.*, 2015, **94**, 3–12.
- 346 E. J. Carragee, E. L. Hurwitz and B. K. Weiner, *J. Spine*, 2011, **11**, 471–491.
- 347 L. Lao, J. R. Cohen, Z. Buser, D. S. Brodke, S. T. Yoon, J. A. Youssef, J.-B. Park, H.-J. Meisel and J. C. Wang, *Glob. Spine J.*, 2018, **8**, 137–141.
- 348 R. Fu, S. Selph, M. McDonagh, K. Peterson, A. Tiwari, R. Chou and M. Helfand, *Ann. Intern. Med.*, 2013, **158**, 890–902.
- 349 N. E. Epstein, *Surg. Neurol. Int.*, 2014, **5**, S552–S560.
- 350 J. K. Burkus, M. F. Gornet, C. A. Dickman and T. A. Zdeblick, *J. Spinal Disord. Tech.*, 2002, **15**, 337–349.
- 351 J. K. Burkus, S. E. Heim, M. F. Gornet and T. A. Zdeblick, *J. Spinal Disord. Tech.*, 2003, **16**, 113–122.
- 352 S. M. Hansen and R. C. Sasso, *J. Spinal Disord. Tech.*, 2006, **19**, 130–134.
- 353 R. Vaidya, A. Sethi, S. Bartol, M. Jacobson, C. Coe and J. G. Craig, *J. Spinal Disord. Tech.*, 2008, **21**, 557–562.
- 354 R. Vaidya, R. Weir, A. Sethi, S. Meisterling, W. Hakeos and C. D. Wybo, *J. Bone Jt. Surg., Br. Vol.*, 2007, **89-B**, 342–345.
- 355 E. J. Carragee, E. L. Hurwitz and B. K. Weiner, *Spine J.*, 2011, **11**, 471–491.
- 356 E. J. Carragee, K. A. Mitsunaga, E. L. Hurwitz and G. J. Scuderi, *Spine J.*, 2011, **11**, 511–516.
- 357 C. D. Jarrett, J. G. Heller and L. Tsai, *J. Spinal Disord. Tech.*, 2009, **22**, 559–564.
- 358 B. U. Kang, W. C. Choi, S. H. Lee, S. H. Jeon, J. D. Park, D. H. Maeng and Y. G. Choi, *J. Neurosurg. Spine*, 2009, **10**, 60–65.
- 359 R. C. Sasso, N. M. Best, P. V. Mummaneni, T. M. Reilly and S. M. Hussain, *Spine*, 2005, **30**, 670–674.
- 360 R. C. Sasso, S. H. Kitchel and E. G. Dawson, *Spine*, 2004, **29**, 113–122; discussion 121–112.
- 361 L. Y. Carreon, S. D. Glassman, M. Djurasovic, M. J. Campbell, R. M. Puno, J. R. Johnson and J. R. Dimar 2nd, *Spine*, 2009, **34**, 238–243.
- 362 M. P. Garrett, U. K. Kakarla, R. W. Porter and V. K. Sonntag, *Neurosurgery*, 2010, **66**, 1044–1049; discussion 1049.
- 363 M. C. Simmonds, J. V. Brown, M. K. Heirs, J. P. Higgins, R. J. Mannion, M. A. Rodgers and L. A. Stewart, *Ann. Intern. Med.*, 2013, **158**, 877–889.
- 364 R. W. Haid Jr., C. L. Branch Jr., J. T. Alexander and J. K. Burkus, *Spine J.*, 2004, **4**, 527–538; discussion 538–529.
- 365 V. Joseph and Y. R. Rampersaud, *Spine*, 2007, **32**, 2885–2890.
- 366 H. J. Meisel, M. Schnöring, C. Hohaus, Y. Minkus, A. Beier, T. Ganey and U. Mansmann, *Eur. Spine J.*, 2008, **17**, 1735–1744.
- 367 D. A. Wong, A. Kumar, S. Jatana, G. Ghiselli and K. Wong, *Spine J.*, 2008, **8**, 1011–1018.
- 368 P. T. Geibel, D. L. Boyd and V. Slabisak, *J. Spinal Disord. Tech.*, 2009, **22**, 315–320.
- 369 A. T. Villavicencio, S. Burneikiene, E. L. Nelson, K. R. Bulsara, M. Favors and J. Thramann, *J. Neurosurg. Spine*, 2005, **3**, 436–443.
- 370 J. A. Rihn, J. Makda, J. Hong, R. Patel, A. S. Hilibrand, D. G. Anderson, A. R. Vaccaro and T. J. Albert, *Eur. Spine J.*, 2009, **18**, 1629–1636.
- 371 J. A. Rihn, R. Patel, J. Makda, J. Hong, D. G. Anderson, A. R. Vaccaro, A. S. Hilibrand and T. J. Albert, *Spine J.*, 2009, **9**, 623–629.
- 372 S. Balseiro and E. W. Nottmeier, *Spine J.*, 2010, **10**, e6–e10.
- 373 G. A. Helm, H. Dayoub and J. A. Jane, *Neurosurg. Focus*, 2001, **10**, E4.
- 374 F. Kandziora, G. Schmidmaier, G. Schollmeier, H. Bail, R. Pflugmacher, T. Görke, M. Wagner, M. Raschke, T. Mittlmeier and N. P. Haas, *Spine*, 2002, **27**, 1710–1723.



- 375 B. M. Holzapfel, J. C. Reichert, J. T. Schantz, U. Gbureck, L. Rackwitz, U. Nöth, F. Jakob, M. Rudert, J. Groll and D. W. Huttmacher, *Adv. Drug Delivery Rev.*, 2013, **65**, 581–603.
- 376 S. A. Abbah, C. X. L. Lam, D. W. Huttmacher, J. C. H. Goh and H.-K. Wong, *Biomaterials*, 2009, **30**, 5086–5093.
- 377 J. N. Zara, R. K. Siu, X. Zhang, J. Shen, R. Ngo, M. Lee, W. Li, M. Chiang, J. Chung, J. Kwak, B. M. Wu, K. Ting and C. Soo, *Tissue Eng., Part A*, 2011, **17**, 1389–1399.
- 378 B.-B. Seo, J.-T. Koh and S.-C. Song, *Biomaterials*, 2017, **122**, 91–104.
- 379 Z. Wang, Z. Wang, W. W. Lu, W. Zhen, D. Yang and S. Peng, *NPG Asia Mater.*, 2017, **9**, e435–e435.
- 380 I. R. Calori, G. Braga, P. d. C. C. de Jesus, H. Bi and A. C. Tedesco, *Eur. Polym. J.*, 2020, **129**, 109621.
- 381 S. Vukicevic, H. Oppermann, D. Verbanac, M. Jankolija, I. Popek, J. Curak, J. Brkljacic, M. Pauk, I. Erjavec, I. Francetic, I. Dumic-Cule, M. Jelic, D. Durdevic, T. Vlahovic, R. Novak, V. Kufner, T. Bordukalo Niksic, M. Kozlovic, Z. Banic Tomisic, J. Bubic-Spoljar, I. Bastalic, S. Vikić-Topic, M. Peric, M. Pecina and L. Grgurevic, *Int. Orthop.*, 2014, **38**, 635–647.
- 382 J. R. Dimar 2nd, S. D. Glassman, J. K. Burkus, P. W. Pryor, J. W. Hardacker and L. Y. Carreon, *Spine J.*, 2009, **9**, 880–885.
- 383 S. L. Ondra and S. Marzouk, *Neurosurg. Focus*, 2003, **15**, 1–5.
- 384 N. M. Raizman, J. R. O'Brien, K. L. Poehling-Monaghan and D. Y. Warren, *J. Am. Acad. Orthop. Surg.*, 2009, **17**, 494–503.
- 385 M. G. Kaiser, M. W. Groff, W. C. Watters, Z. Ghogawala, P. V. Mummaneni, A. T. Dailey, T. F. Choudhri, J. C. Eck, A. Sharan, J. C. Wang, S. S. Dhall and D. K. Resnick, *J. Neurosurg. Spine*, 2014, **21**, 106.
- 386 T. H. Smit, T. A. Engels, P. I. Wuisman and L. E. Govaert, *Spine*, 2008, **33**, 14–18.
- 387 B. C. Cheng, S. Jaffee, S. Averick, I. Swink, S. Horvath and R. Zhukauskas, *Spine J.*, 2020, **20**, 457–464.
- 388 K. Tanaka, M. Takemoto, S. Fujibayashi, M. Neo, Y. Shikinami and T. Nakamura, *Spine*, 2011, **36**, 441–447.
- 389 D. C. Fredericks, E. B. Petersen, N. Sahai, K. G. N. Corley, N. DeVries, N. M. Grosland and J. D. Smucker, *Iowa Orthop. J.*, 2013, **33**, 25–32.
- 390 J. D. Smucker, E. B. Petersen, J. V. Nepola and D. C. Fredericks, *Iowa Orthop. J.*, 2012, **32**, 61–68.
- 391 A. M. Riordan, R. Rangarajan, J. W. Balts, W. K. Hsu and P. A. Anderson, *J. Orthop. Res.*, 2013, **31**, 1261–1269.
- 392 S. Lee, X. Zhang, J. Shen, A. W. James, C. G. Chung, R. Hardy, C. Li, C. Girgius, Y. Zhang, D. Stoker, H. Wang, B. M. Wu, B. Peault, K. Ting and C. Soo, *Stem Cells*, 2015, **33**, 3158–3163.
- 393 W. Li, M. Lee, J. Whang, R. K. Siu, X. Zhang, C. Liu, B. M. Wu, J. C. Wang, K. Ting and C. Soo, *Tissue Eng., Part A*, 2010, **16**, 2861–2870.
- 394 Q. Ye, K. Chen, W. Huang, Y. He, M. Nong, C. Li and T. Liang, *Exp. Ther. Med.*, 2015, **9**, 25–32.
- 395 Y. Wen, S. Xun, M. Haoye, S. Baichuan, C. Peng, L. Xuejian, Z. Kaihong, Y. Xuan, P. Jiang and L. Shibi, *Biomater. Sci.*, 2017, **5**, 1690–1698.
- 396 H. Yoshikawa, N. Tamai, T. Murase and A. Myoui, *J. R. Soc., Interface*, 2009, **6**(Suppl 3), S341–S348.
- 397 F. Salamanna, D. Contartese, G. Tedesco, A. Ruffilli, M. Manzetti, G. Viroli, M. Traversari, C. Faldini and G. Giavaresi, *JOR Spine*, 2024, **7**, e1347.
- 398 M. A. Plantz and W. K. Hsu, *Curr. Rev. Musculoskelet. Med.*, 2020, **13**, 318–325.
- 399 E. J. Kerr 3rd, A. Jawahar, T. Wooten, S. Kay, D. A. Cavanaugh and P. D. Nunley, *J. Surg. Orthop. Adv.*, 2011, **20**, 193–197.
- 400 J. M. Ammerman, J. Libricz and M. D. Ammerman, *Clin. Neurol. Neurosurg.*, 2013, **115**, 991–994.
- 401 B. Johnstone, N. Zhang, E. I. Waldorff, E. Semler, A. Dasgupta, M. Betsch, P. Punsalan, H. Cho, J. T. Ryaby and J. Yoo, *Int. J. Spine Surg.*, 2020, **14**, 213–221.
- 402 C. Lin, N. Zhang, E. I. Waldorff, P. Punsalan, D. Wang, E. Semler, J. T. Ryaby, J. Yoo and B. Johnstone, *JOR Spine*, 2020, **3**, e1084.
- 403 P. C. Hsieh, Z. Buser, A. C. Skelly, E. D. Brodt, D. Brodke, H. J. Meisel, J. B. Park, S. T. Yoon and J. C. Wang, *Global Spine J.*, 2019, **9**, 22s–38s.
- 404 B. W. Cunningham, B. L. Atkinson, N. Hu, J. Kikkawa, L. Jenis, J. Bryant, P. O. Zamora and P. C. McAfee, *J. Neurosurg. Spine*, 2009, **10**, 300–307.
- 405 P. Lauweryns and Y. Raskin, *Int. J. Spine Surg.*, 2015, **9**, 2.
- 406 J. J. Qian and R. S. Bhatnagar, *J. Biomed. Mater. Res.*, 1996, **31**, 545–554.
- 407 A. Kadam, P. W. Millhouse, C. K. Kepler, K. E. Radcliff, M. G. Fehlings, M. E. Janssen, R. C. Sasso, J. J. Benedict and A. R. Vaccaro, *Int. J. Spine Surg.*, 2016, **10**, 33.

